{
  "name" : "dacemirror.sci-hub.se_journal-article_4ca26d9cae73a7718a95b1da13d5d7d6_zhang2019.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Molecular Engineering of Functional Nucleic Acid Nanomaterials toward In Vivo Applications",
    "authors" : [ "JingJing Zhang", "Tian Lan", "Yi Lu" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "www.advhealthmat.de\nPROGRESS REPORT\n1801158 (1 of 24) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim"
    }, {
      "heading" : "Molecular Engineering of Functional Nucleic Acid",
      "text" : ""
    }, {
      "heading" : "Nanomaterials toward In Vivo Applications",
      "text" : ""
    }, {
      "heading" : "JingJing Zhang, Tian Lan,* and Yi Lu*",
      "text" : "DOI: 10.1002/adhm.201801158\nequally exciting and perhaps more challenging field of application is toward their in vivo applications, including living animals and human bodies, in diverse areas,[2] such as sensing, drug delivery, medical imaging, and cancer therapy. However, most of these nanomaterials lack selectivity toward targets of interests. Therefore, to employ these nanomaterials for a wider range of in vivo applications, various molecular engineering approaches have been employed to obtained nanomaterials functionalized with biomolecules to enable selective targeting.[3–5] Among these biomolecules, functional nucleic acids, or FNAs, have shown the most promise.\nFNAs are DNA or RNA molecules that can interact with or bind to a specific analyte, resulting in a conformational change and/or a catalytic reaction.[6] As their names suggested, ribozymes and deoxyribozymes (called DNAzyme hereafter) can act as enzymes in the\npresence of cofactors to catalyze various reactions, including cleavage and ligation of RNA/DNA, and phosphorylation and peroxidation of DNA. On the other hand, riboswitches and DNA aptamers are antibody-like receptors that can bind target molecules with high affinity and selectivity. Furthermore, the binding abilities of riboswitches and aptamers can be combined with the enzymatic function of ribozymes or DNAzymes to form aptazymes so that the binding of targets can inhibit or enhance the catalytic activities. These nucleic acids, including DNAzymes, aptamers, and aptazymes, are collectively known as FNAs to emphasize their functions beyond the traditional genetic storage and transformations roles for DNA and RNA. Unlike DNA and RNA inside biological systems, FNAs are isolated via a combinatorial technique known as in vitro selection, or a process also known as systematic evolution of ligands by exponential enrichment (SELEX). The discovery of new functions of nucleic acids has not only resulted in major advances in the fields of molecular biology and biochemistry, but also revolutionized sensors designs for both in vitro and in vivo applications.[7,8]\nOver the past decade, numerous FNA-based nanomaterials have been developed.[9–12] Among these FNA-based nanosystems, the functions of FNAs can be categorized into two types: diagnostic function and therapeutic function. For the diagnostic function, the FNAs serve either as the biorecognition ligands for direct sensing and imaging of the\nRecent advances in nanotechnology and engineering have generated many nanomaterials with unique physical and chemical properties. Over the past decade, numerous nanomaterials are introduced into many research areas, such as sensors for environmental monitoring, food safety, point-ofcare diagnostics, and as transducers for solar energy transfer. Meanwhile, functional nucleic acids (FNAs), including nucleic acid enzymes, aptamers, and aptazymes, have attracted major attention from the biomedical community due to their unique target recognition and catalytic properties. Benefiting from the recent progress of molecular engineering strategies, the physicochemical properties of nanomaterials are endowed by the target recognition and catalytic activity of FNAs in the presence of a target analyte, resulting in numerous smart nanoprobes for diverse applications including intracellular imaging, drug delivery, in vivo imaging, and tumor therapy. This progress report focuses on the recent advances in designing and engineering FNA-based nanomaterials, highlighting the functional outcomes toward in vivo applications. The challenges and opportunities for the future translation of FNA-based nanomaterials into clinical applications are also discussed."
    }, {
      "heading" : "Functional Nucleic Acid",
      "text" : "Dr. J. Zhang, Prof. Y. Lu Department of Chemistry University of Illinois at Urbana–Champaign 601 S. Mathews Ave., Urbana, IL 61801, USA E-mail: yi-lu@illinois.edu Dr. T. Lan GlucoSentient, Inc. 2100 S. Oak Street Suite 101, Champaign, IL 61820, USA E-mail: tlan@glucosentient.com\nThe ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/adhm.201801158."
    }, {
      "heading" : "1. Introduction",
      "text" : "Recent advances in nanotechnology and engineering have generated many nanomaterials with unique physical and chemical properties,[1] such as noble metal nanomaterials with localized surface plasmon resonances, upconversion nanoparticles (UCNPs) with nonlinear optical processes, semiconductor quantum dots (QDs) with size-tunable photoluminescence (PL), and carbon nanomaterials with broad absorbance from UV to NIR regions. As a result, much efforts have devoted toward applying these nanomaterials for applications, such as sensors for environmental monitoring, food safety, point-of-care diagnostics, and as transducers for solar energy transfer. An\nAdv. Healthcare Mater. 2019, 1801158\n1801158 (2 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nspecific targets,[10] or as the biocatalysts to produce signal amplification for indirect sensing and imaging of other targets of interest.[13] On the other hand, for the therapeutic function, the FNAs could be directly used as the therapeutic drugs for some diseases[14] or serve as the host of other therapeutic reagents,[15] including anticancer drugs, miRNAs, and siRNAs. As a result, the combination of the diagnostic and therapeutic functions of FNAs with the diverse and strong signal transduction of nanomaterials has become a major active area of research with many exciting results. In this review, we highlight recent advances in molecular engineering of functional nucleic acid–based nanomaterials, focusing on noble metal nanomaterials, carbon nanomaterials, and nucleic acid nanostructures, and other representative nanomaterials, as well as their applications toward in vivo studies (Figure 1)."
    }, {
      "heading" : "2. Molecular Engineering of Nucleic Acid Enzyme–Based Nanomaterials toward In Vivo Applications",
      "text" : "Nucleic acid enzymes (NAEs) are a class of catalytic nucleic acids, which generally can be obtained by in vitro selection, and therefore are more stable and easier for modification and preparation than natural protein enzymes. Up to now, a large number of NAEs have been developed to catalyze a wide range of reactions, in which RNA-cleaving NAEs have been the most extensively studied and widely used in biological applications[16] due to their outstanding properties, such as generally catalytically efficient and easily integration with signal transduction nanomaterials via RNA cleavage. However, the most significant challenge for using NAEs in vivo is their nontoxic delivery while maintaining the functions. Over the past decade, by combining with a variety of nanomaterials, NAE-based nanomaterials have been developed to achieve a large number of special applications toward in vivo studies.[16,17]"
    }, {
      "heading" : "2.1. Integration of Nucleic Acid Enzymes with Noble Metal Nanomaterials",
      "text" : "Noble metal nanomaterials, particularly gold nanoparticles (AuNPs), have attracted much attention during the past decades due of their excellent properties such as high stability, strong plasmonic effects, efficient catalysis, and low cytotoxicity. Another significant advantages of using gold nanomaterials in in vivo applications are their use as carriers to facilitate the cellualr entry of other materials, such as DNA, antitumor drugs, or small organic dyes. Using this feature to their advantage, Yehl et al. synthesized multivalent 10–23 DNAzyme–AuNP conjugates (DzNPs) as shown in Figure 2A.[18] They have demonstrated that DzNPs are less susceptible to nuclease degradation, readily enter mammalian cells, and catalytically downregulate GDF15 gene expression levels in breast cancer cells in an RNA interference-independent pathway. By using AuNPs as the carrier, some of the key limitations in the adoption of DNAzymes in in vivo application were addressed. Later in 2016, Somasuntharam et al. used a similar design to catalytically silence\nTian Lan received his Ph.D. degree in biochemistry under the supervision of Prof. Yi Lu from the school of molecular and cellular biology at the University of Illinois at Urbana–Champaign in 2011. Currently, he is working as the lead scientist at GlucoSentient on diagnostic product development.\nYi Lu received his Ph.D. degree from the University of California at Los Angeles in 1992. He is now a Jay and Ann Schenck Professor of Chemistry in the Departments of Chemistry, Biochemistry, Bioengineering and Materials Science and Engineering. His research interests include design and engineering of functional\nmetalloproteins as environmentally benign catalysis in renewable energy generation and pharmaceuticals; fundamental understanding of DNAzymes and their applications in environmental monitoring, medical diagnostics, and targeted drug delivery; and employing principles from biology for directed assembly of nanomaterials with controlled morphologies and their applications in imaging and medicine.\nJingJing Zhang received his Ph.D. degree in chemistry under the supervision of Prof. Jun-Jie Zhu from the School of Chemistry and Chemical Engineering, Nanjing University, in 2010. Currently, he works as a postdoctoral research associate in the group of Prof. Yi Lu at the University of Illinois Urbana–Champaign\nsince March 2012. His research interests focus on interfacing carbon and gold nanomaterials with biological systems, and developing novel tools for imaging, sensing, and diagnostics.\nAdv. Healthcare Mater. 2019, 1801158\n1801158 (3 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nthe gene expression of tumor necrosis factor-α (TNF-α) in vivo as a potential therapeutic for myocardial infarction (MI) (Figure 2B).[19] They demonstrated that DzNPs can serve as effective anti-inflammatory agents in the heart by regulating TNF-α expression in a rodent model of acute MI and confer therapeutic benefits to the damaged heart. This is the first example of DzNPs for viable delivery and gene regulation in vivo. Another smart strategy for DNAzyme-based gene regulation was developed by He et al. using a dual-functional probe composed of AuNPs, catalytic Zn2+-dependent DNAzyme, anticancer drug doxorubicin (DOX), targeted AS1411 aptamer, and acid-decomposable ZnO QDs.[20] Using AS1411 aptamer for targeting the receptors involved in cellular entry, the probes could be selectively delivered into the HeLa cells through endocytosis and then retained in the acidic endosomes or lysosomes, where the ZnO QDs were rapidly dissolved to release Zn2+. The Zn2+ released activated the DNAzyme and led to substrate cleavage followed by drug release; at the same time, the cleaved substrate was designed to complement with the overexpressed miR-21 in the HeLa cells, thereby downregulating the intracellular level.\nIn addition to gene regulation, NAE-based AuNPs can also serve as probes for sensing and imaging metal ions inside cells. For instance, the first DNAzyme-based nanoprobe for imaging of metal ions in live cells was recently developed by Wu et al.[21] In their design, 13 nm AuNPs served not only as a carrier for uranyl-specific 39E DNAzyme and 39S DNAzyme substrate strand labeled with a Cy3 fluorophore at the 5′ end and a quencher at the 3′ end, but also as a quencher for the Cy3 fluorophore (Figure 2C). Upon the addition of UO22+, the DNAzyme cleaved the substrate strand to release the shorter Cy3-labeled substrate strand, and thereby increasing the fluorescence. Using the similar method, Li et al. designed a two-color fluorescence nanoprobe based on the DNAzyme-modified AuNPs and demonstrated the simultaneous on-site imaging of the Zn2+ and Cu2+ in living cells.[22] In addition to metal ions imaging in living cells, Yang el at. recently developed a DNAzyme-based two-photon imaging probe (TP-8−17ES−AuNP) for Zn2+ imaging in deep tissues with a penetration depth up to 160 µm,[23] by modifying a Zn2+-specific DNAzyme (8−17) with a TP fluorophore and using AuNPs for intracellular delivery. Another significant advancement in intracellular imaging of metal ions was the “on-demand” activation of DNAzymes by light.[24,25] In this way, nonspecific cleavage of DNAzymes during their delivery into cells can be prevented, and metal ion imaging can be controlled both temporally and spatially by light. One innovative example for light-controlled activation of DNAzyme-based nanoprobe was reported by Wang et al.,[26] where a near-infrared (NIR) photothermal activation system was developed. The system composed of a three-stranded DNAzyme precursor (TSDP) covalently attached to gold nanoshells. In the ground state, the TSDP was inactive. Upon NIR illumination, the temperature increased and the hybridization keeping the DNAzyme inactivated denatured and the DNAzyme became activated. Finally, the activated DNAzyme catalyzed the metal ion–dependent reaction, releasing the product containing a fluorophore.\nAdv. Healthcare Mater. 2019, 1801158\n1801158 (4 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nDue to the sequence specificity of NAEs, another important application of NAE-based gold nanomaterials is microRNA (miRNA) imaging and expression control. Regulation of miRNA expression has been shown to be involved in the initiation and progression of cancer, hence a potential target for cancer therapy. In light of this discovery, Zhang et al. developed an miRNA imaging and potential drug release approach using multicomponent nucleic acid enzymes (MNAzymes) conjugated on the surface of silica-coated gold nanorods (Figure 2D).[27] After cellular uptake, the targeted miR-21 and miR-145 hybridized to the binding arms of the MNAzyme and activated the MNAzyme to cleave the fluorophore-labeled substrate to generate a fluorescent signal for intracellular miRNA imaging. At the same time, the substrate cleavage triggered conformational change of the MNAzyme also served as an uncapping mechanism, leading to the release of the encapsulated chemotherapeutics. This work provided a general strategy for disease diagnosis, prognosis, and combo treatment using chemo- and gene therapy. Later, to further improve the sensitivity of miRNAs imaging inside cells, a number of amplified sensing platforms based on DNAzymes–AuNPs have been reported, including a AuNP-based DNAzyme motor,[28] a AuNP-based hairpin-locked-DNAzyme probe,[29] a AuNP-based DNAzyme nanomachine,[30] as well as a AuNP loaded splitDNAzyme probe.[31] These multitude of DNAzyme–AuNP probes demonstrate a significant advancement toward in vivo amplified detection and imaging of various analytes. 2.2. Integration of Nucleic Acid Enzymes with Carbon Nanomaterials Carbon nanomaterials, including carbon nanotubes (CNTs) and graphene, have gained substantial research interest in biomedical and bioanalytical fields because of their unique properties of good biocompatibility, high internalization efficiency, easy functionalization, excellent quenching ability to a broad range of fluorophores, and protection of conjugated DNA from enzymatic cleavage. In recent years, the integration of carbon nanomaterials with NAEs has been found to be practical in in vivo applications. One promising direction is to use the carbon nanomaterials as a carrier to immobilize the NAEs. For example, Li et al. (Figure 3A) demonstrated a DNAzyme-based walker system as a controlled release platform for a therapeutic aptamer, AS1411, for breast cancer treatment.[32] In this system, the\nAdv. Healthcare Mater. 2019, 1801158\n1801158 (5 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\n10–23 DNAzyme (green) was first conjugated with a CdTe/CdS QD (orange), and then moved along the CNT track (black) in the presence of Mg2+, leading to the release of the anticancer oligonucleotide AS1411 (light blue) from the anchor strand (navy). The released Cy5 dye–labeled AS1411 (red) further formed a dimeric G-quadruplex structure in the presence of K+, resulting in the antiproliferation of MCF-7 cells.\nIn addition to serve as a carrier for NAEs, carbon nanomaterials can also be used to quench the fluorescence of fluorophores for imaging applications. For instance, Si et al. (Figure 3B) reported an NAE-based nanoprobe, consisting of a DNAzyme, a hairpin probe, and graphene oxide (GO) as intracellular carrier and quencher, and demonstrated its application for the highly sensitive detection and simultaneous in situ imaging of Zn2+ and Cu2+ in living cells.[33] A signal amplification was obtained based on DNA self-assembly with DNAzyme catalysis in the presence of targeted metal ions. Later, Gao et al. developed another signal amplification strategy based on a proximity binding assay on GO integrated with Pb2+–DNAzyme assistant probe recycling. Using this DNAzyme–GO nanoprobe, the detection and imaging of ATP in living cells was achieved.[34]"
    }, {
      "heading" : "2.3. Integration of Nucleic Acid Enzymes with Nucleic Acid Nanostructures",
      "text" : "Nucleic acid is also a viable material for the bottom-up assembly of nanoscale structures.[35] In recent decades, the emerging DNA nanotechnology provides a new route to fabricate various nucleic acid nanostructures via programmable DNA base pairing. Combining NAEs with nucleic acid nanostructures can provide new hybrid systems for in vivo applications. For instance, by modifying the edges of DNA tetrahedron with two DNAzymes, Zhou et al. (Figure 4A) designed a dual color–encoded DNAzyme-based nanoprobe for simultaneously detection of intracellular metal ions, UO22+ and Pb2+.[36] However, a significant issue is that it needs an additional influx of metal ions to increase their intracellular concentration to detect a response. To address this issue, Wu et al. developed a novel method to amplify the signal from DNAzyme-catalyzed cleavage for detection of low levels of intracellular metal ions to better understand the roles that metal ions play in biological systems.[37] As shown in Figure 4B, by employing a hairpin structure, the probe consists of a Na+-specific DNAzyme (NaA43) and a catalytic hairpin assemble (CHA). Upon\nAdv. Healthcare Mater. 2019, 1801158\n1801158 (6 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimAdv. Healthcare Mater. 2019, 1801158\n1801158 (7 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nactivation from light and Na+ exposure, the NaA43 DNAzyme cleaved the substrate and released a product stand, and this product strand triggered the subsequent CHA amplification to generate a turn-on fluorescence signal. This method can be employed to detect cellular metal ions in general with a DNAzyme and can have a potential to elucidate the roles of metal ions in biological systems.\nBesides intracellular metal ion imaging, NAE-based nucleic acid nanostructures have also been used for gene regulation,[38] enhanced cancer therapy,[39] and imaging of tumor-associated membrane protein.[40] For example, Jin et al. reported an NAEbased cancer therapeutic system with targeted gene silencing and cancer therapy by using a rolling circle amplification (RCA) method (Figure 4C).[39] In this construct, AS1411 aptamer, an EGR-1 (early growth response-1) DNAzyme, and a surviving DNAzyme were self-assembled into a single DNA nanoflower (DNF) by using a long ssDNA product obtained from RCA and magnesium pyrophosphate. The resultant DNF was capable for cancer cell recognition, multiple gene silencing, and induction of apoptosis. Similarly, by replacing magnesium pyrophosphate with a cationic polymer, the same group further developed a sponge-like platform for high-efficiency photothermal therapy (Figure 4D).[41] Similarly, Li et al. developed a multifunctional DNA nanosorption nanostructure using aptamers and DNAzyme for highly efficient targeted delivery and release of therapeutic mRNA for gene therapy.[42]"
    }, {
      "heading" : "2.4. Integration of Nucleic Acid Enzymes with Other Nanomaterials",
      "text" : "Magnetic nanoparticles (MNPs) have also been combined with NAEs for various in vivo applications. For example, Ryoo et al. reported an iron oxide nanoparticle-based system for the delivery of therapeutic DNAzyme for the treatment of hepatitis C (Figure 5A),[43] by downregulating NS3, a hepatitis C virus (HCV) gene, with no undesired immune responses or cytotoxicity. This delivery system was constructed by the conjugation of DNAzyme recognizing the NS3 sequence with iron oxide nanoparticles modified with cell-penetrating peptide. They demonstrated that the DNAzyme-conjugated nanoparticle system can be applied in vivo by showing the accumulation of these nanoparticles in hepatocytes. Recently, Bakshi et al. reported DNAzyme sensory system (MaBiDz) that can be activated upon a change in magnetic field and the system was demonstrated for intracellular sensing of specific mRNA (Figure 5B).[44] The magnetic field–dependent DNAzyme activation was achieved by magnetic field–triggered assembly of two components of the DNAzyme to form the active site for catalysis. The MaBiDz sensor was deployed successfully for rapid intracellular detection and imaging of a target mRNA biomarker for metastatic breast cancer. The application of MaBiDz sensor can further be expanded for mRNA regulation in a biomimetic organelle.\nRecently, biodegradable MnO2 nanosheets are also promoted as a new type of carrier to deliver NAEs for various diagnostic and therapeutic applications, with their appealing physicochemical properties such as acting as a good ssDNA carrier, an abundant reservoir of Mn2+ to activate 10–23 DNAzyme when reduced by intracellular glutathione (GSH), efficient\nquencher for broad-spectrum fluorescence, and finally, activatable magnetic resonance and fluorescence signaling for imaging applications. For example, Fan et al. have developed a smart DNAzyme–MnO2 nanosystem for gene silencing and intracellular imaging.[45] The system was constructed by conjugating photosensitizer Ce6-modified 10–23 DNAzyme with MnO2 nanosheet to achieve a dual function gene silencing and photodynamic therapy (PDT) agent. This dual function agent demonstrated a remarkably improved therapeutic effect over that of gene silencing or PDT therapy alone. Additionally, Chen et al. (Figure 5C) further demonstrated that the combination of MnO2−nanosheet with DNAzyme can also function as a catalytic DNA circuit generator for intracellular signal amplification to monitor DNA base-excision repairs in cells.[46] Similarly, employing MnO2 nanosheets as DNAzyme carriers, the above group also introduced a general method for programming and assembly nanodevices with enzyme-activated DNAzymes (Figure 5D).[47] With this approach, it can not only monitor enzyme activity in situ but also enable the implementation of cellular stages, behaviors, and pathways for basic science, diagnostic, and therapeutic applications as genetic circuits. Recently, silencing multiple genes in cells and in vivo was also reported by Li et al.[48] by using a novel DNAzyme-based nanocomposite (Figure 5E). In this system, cobalt oxyhydroxide (CoOOH) as a nanocarrier and oxidizing agent can be reduced by intracellular GSH, and the Co2+ as a reaction product and cofactor catalyzes 10–23 DNAzymes to cleave relevant mRNAs for gene silencing. The nanocomposite can simultaneously cleave three different tumor-related mRNAs in living cells and perform outstandingly toward the inhibition of cancer cells’ migration, invasion, and proliferation, and finally inhibit the tumor formation in a mouse model.\nIn addition to the above nanomaterials, NAEs have also been integrated with dendritic polyethylene–cationic poly(pphenylene ethynylene),[49] metal−organic frameworks (MOFs),[50] UCNPs,[51] and cationic polypeptides,[52] for intracellular imaging of molecules, such as metal ions, miRNAs, and messenger ribonucleic acids (mRNAs). As an example, Torabi et al.[52] reported the isolation of the first Na+ specific RNA cleaving DNAzyme with high selectivity, sensitivity, and efficiency (Figure 5F). The Na+ DNAzyme was further converted into a catalytic beacon sensor for intracellular imaging Na+ using an efficient cationic polypeptide delivery method. Furthermore, light-responsive activation was achieved by including a photocaging group at the cleavage site. Based on these studies, we summarize the representative reports focusing on NAEs integrated with other nanomaterials, as shown in Table 1."
    }, {
      "heading" : "3. Molecular Engineering of Aptamer-Based Nanomaterials toward In Vivo Applications",
      "text" : "Aptamers are single-stranded nucleic acid sequences that bind to specific targets through binding pockets formed with distinctive 3D structures. Similar to DNAzymes, aptamers are usually isolated through an in vitro SELEX or whole-cell based SELEX. Aptamers have several advantages including a wide variety of molecular targets with high binding specificity and affinity, rapid and reliable synthesis, good reproducibility, flexibility, and\nAdv. Healthcare Mater. 2019, 1801158\n1801158 (8 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimAdv. Healthcare Mater. 2019, 1801158\n1801158 (9 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nstable for long-term storage and transportation at ambient conditions. These advantages enable aptamers to be a pro mising molecular receptor, with diverse applications for in vitro detection and imaging of various targets.[53] Aside from in vitro detection, aptamers have also been explored for bioimaging in vivo, which is critical for disease diagnosis, prognosis, patient stratification, and monitoring treatment response. Compared to antibodies, the convenient conjugation, rapid penetration, and clearance represent the most significant advantages of aptamers for in vivo bioimaging.[53] In addition, aptamers can also be utilized as therapeutics due to their ability to bind and inhibit protein functions.[54] To date, a few therapeutic aptamers have made successful transition to clinical trials and commercial product, including pegaptanib for the treatment of age-related macular degeneration (AMD) and AS1411 for the treatment of cancer, and pegnivacogin as anticoagulants.\nDespite these advances, however, a few aptamer-based diagnostic or therapeutic products are on the market. From the perspective of in vivo applications, aptamers without specific modification are negatively charged and naturally repelled from the cell membrane that carries the same charge, hence, limiting their ability to cross the cell membrane.[55] Moreover, aptamers without protecting modifications are susceptible to degradation by nucleases inside the cellular matrix. As a result, it is necessary to combine and protect aptamers with additional carriers to improve cellular entry and resistance to nuclease. Nanomaterials are receiving significant attention in biochemical analysis and in vivo imaging due to their unique small sizes, large surface to volume, good biocompatibility, and distinctive chemical, optical and electrical properties. Consequently, nanomaterials have been demonstrated to be outstanding delivery vehicles for their high loading efficiency of cargos, such as DNAs, drugs, or other molecules, as well as protection against nuclease degradation. Therefore, the integration of nanomaterials with aptamers have opened up exciting avenues for in vivo applications.[10]"
    }, {
      "heading" : "3.1. Integration of Aptamers with Noble Metal Nanomaterials",
      "text" : "Among various noble metal nanomaterials, gold nanomaterials are most intensely investigated as imaging contrast agents and nanocarriers.[56] As a result, the integration of aptamer with gold nanomaterials, such as Au nanorods (AuNRs),[57] Au nanoparticles,[58–72] Au nanocages,[73,74] Au nanostars (AuNSs),[75,76] hollow gold nanospheres (HAuNS),[77] and Au nanoclusters (Au NCs),[78] has been widely employed in in vivo applications in diverse areas, such as intracellular molecular imaging,[63,68] cancer cell and tumor imaging,[57,58,65,66,69,73,77,78] targeted delivery of therapeutic cargos (e.g., anticancer drug,[74] protein,[61] and gene[62]), and cancer therapy.[59,60,70,75,76] In one example, Huang et al. demonstrated the use of AuNRs as an efficient and robust multivalent platform for molecular assembly of aptamers for targeted cell imaging.[57] Based on the strong localized surface plasmon resonance of AuNPs, Javier et al. devised prostate-specific membrane antigen (PSMA)–aptamer-modified gold nanoparticles for use as contrast agents for reflectance imaging of PSMA(+) and PSMA(−) cell lines.[58] Using the same PSMA aptamer, Kim et al. further designed the aptamer–AuNPs with loading of doxorubicin for additional chemotherapeutic effects against prostate cancer cells.[59] To improve the drug loading efficiency for cancer therapy, Zheng et al. engineered a spherical nucleic acid (SNA) by designing a cascade of hybridizations initiated from a AuNP-conjugated DNA initiator, and the cascade hybridization resulted in the formation of a nanoparticle shell composed of long DNA polymer.[60] By incorporating an aptamer to this SNA, the final construct showed high drug loading capacity as well as high selectivity. Later, Li et al. developed a system composed of fluorescent AuNPs conjugated with diatrizoic acid and AS1411 aptamer (AS1411–DA–AuNPs),[65] which was successfully deployed as a molecular contrast agent to detect CL1-5 tumor by CT imaging. Recently, DNA–gadolinium– AuNPs that exhibit an improved T1 relaxivity and excellent cell uptake were developed by Nicholls et al. (Figure 6A).[66] These nanoconjugates showed promising application for T1 MRI of transplanted human brain neural stem cells in vivo. Afterward, Tang et al. constructed highly stabilized core satellite Au nanoassemblies (CSAuNAs) by a hierarchical DNAdirected self-assembly strategy,[69] which can be selectively accumulated in the kidneys with satisfactory renal retention capability. Similarly, Si et al. developed versatile drug-loaded nanoprobes based on MUC1 aptamer-integrated AuNPs, and further engineered telomerase-recognition sequence to the\nAdv. Healthcare Mater. 2019, 1801158\n1801158 (10 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimAdv. Healthcare Mater. 2019, 1801158\n1801158 (11 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nnanoprobes, enabling controllable drug release by intracellular telomerase.[71]\nIn addition to targeted cell imaging, aptamer-based gold nanomaterials have also been used for intracellular molecular imaging. For instance, by combining the structure-switching i-motif and the highly selective adenosine triphosphate (ATP) aptamer, Jin et al. developed a dual-stimuli responsive i-motif/ nanoflares for ATP imaging in lysosomes.[63] Later, Chen et al.[68] (Figure 6B) reported the use of polyA-based SNA aptamer nanobeacons (PAaptNBs) that are functionalized with rationally designed polyadenine (polyA) diblock oligonucleotides through they achieved programmable engineering of PAaptNB for intracellular ATP imaging. In addition to ATP imaging, other molecules such as matrix metallopeptidase 3,[64] potassium ions,[67] and cytochrome c (Cyt c)[72] have also been imaged using the aptamer–Au nanoprobes.\nIn addition to aptamer–gold nanomaterials for in vivo applications, silver nanomaterials have also been used,[79–85] among which nucleic acid–stabilized silver nanoclusters (Ag NCs) are the most attractive. Ag NCs possess good fluorescence properties, excellent photostability, sub-nanometer size, as well as low cytotoxicity. In addition, Ag NC fluorescence is highly dependent on the DNA sequence and is sensitive to oligonucleotide surroundings. These unique features make Ag NCs promising candidate for in vivo sensing and imaging. For example, Li et al. rationally connected AS1411 aptamer with poly(cytosine) via a –TTTTT loop and employed it as the scaffold to synthesize Ag NCs through a one-step process.[80] The aptamer–Ag NC nanoprobe not only exhibited good fluorescence properties for cell-type-specific imaging but also retained the anticancer nature of AS1411, and unexpectedly, demonstrated enhanced efficiency of growth inhibition to cancer cells compared with naked AS1411. By coupling Sgc8c aptamerfunctionalized Ag NCs with biotinylated siRNA via a streptavidin bridge, Li et al. designed a multifunctional probe that enabled the specific delivery of siRNA into targeted cells for noninvasive imaging simultaneously.[81] Later, they also developed a second aptamer-functionalized Ag NC with ‘‘light-up’’ and ‘‘spectrumshift’’ response for intracellular mRNA imaging.[82] Recently, to improve the resistance of Ag NCs to nuclease digestion, Han et al. (Figure 6C) utilized L-conformation of DNA (L-DNA) for the preparation of aptamer–Ag NCs.[83] Due to its absence in biological systems, L-DNA is resistant to nuclease digestion and hence has resulted in NCs with much higher intracellular stability than those templated by regular DNA, thus making cell-type-specific imaging possible at physiological conditions, with much lower Ag NC concentration than D-DNA-templated ones. Recently, Liu et al. synthesized target-responsive Ag NC beacon (ASNCB) for multiplex DNAs, small molecule, and protein sensing using a one-pot synthesis.[84] Incorporating an ATP aptamer to trigger ATP-responsive structure transformation of ASNCB, ATP binding event induced ASNCB conformational transition and increased fluorescent signal of silver nanoclusters. Besides NCs, other silver nanomaterials, such as silver nanoparticles[86] and silver decahedral nanoparticles,[87] possess interesting properties, such as metal-enhanced fluorescence that increases the emission intensity of fluorophores nearby. Taking advantage of this feature, Li et al. (Figure 6D) developed a multifunctional theranostic agent based on the\naptamer−silver conjugation and applied it for cancer therapy and fluorescence-enhanced cell imaging.[86] Two aptamers, sgc8 aptamer-targeting PTK7 receptor tyrosine kinase and TDO5 aptamer-targeting heavy µ chains on the surface of Ramos cells, were used to functionalize the AgNPs and showed a good performance toward the induction of apoptosis of targeted cells. In addition, using the fluorescent derivative–labeled aptamers for AgNP functionalization, the aptamer−silver conjugate can also be used for specific enhanced cell imaging via metal-enhanced fluorescence effect, while retaining their low cytotoxicity. A silver decahedral nanoparticle enhanced fluorescence resonance energy transfer (FRET) sensor for targeted cell imaging has also been developed by the same group.[87]\nHybrid metal nanomaterials have also been combined with aptamer for diverse in vivo applications. Shi et al.[88] (Figure 6E) designed an activatable theranostic nanoprobe (ATNP) via self-assembly of activatable aptamer probes (AAPs) on Au@ Ag/Au NPs and applied as a “nanodoctor” for image-guided cancer therapy both in vitro and in vivo. The Au@Ag/Au NPs served as the fluorescence quencher and optical heater, and exhibited a large absorption cross section from 400 to 1100 nm and ≈4.5 times higher capacity for hyperthermia than Au NRs under 980 nm irradiation. By using an S6 aptamer against A549 cancer as the model, the AAP sequence was designed and optimized, which not only showed excellent target recognition ability, but also successfully achieved selective fluorescence activation. In addition, by introducing a target-triggered signal alteration mechanism into the diagnosis principle, this “nanodoctor” substantially enhanced the imaging contrast and shortened the detection time, leading to a fast and potent photothermal therapy (PTT) of cancer. In another case, aptamer-coated Cu–Au alloy nanostructures for in vivo cancer theranostics have been reported by Ye et al. (Figure 6F).[89] The integration of Cu and Au not only solved the problem of functionalization of Cu nanomaterial, but also greatly improved the photostability of the Au nanomaterials, while the introduction of aptamers enabled the efficient localization and accumulation of the nanoprobes in cancer cells and tissues, resulting in the simultaneous fluorescent molecular imaging and NIR PTT of the target cancer. More recently, Hu et al.[90] reported another fluorescent monometallic Ag nanohybrids (Ag NHs) synthesized via polycytosine-mediated Ag NC biomineralization on Ag NPs. The aptamer-functionalized Ag NHs served as an efficient therapeutic agent and can induce reactive oxygen species generation leading apoptosis once it is delivered into target cells.\nOther hybrid metal nanomaterial–aptamer systems, such as AuNP/Ag NCs,[91] DNA-origami–AuNRs hybrid,[92] Mn(II) silver–aptamer clusters,[93] and Au NCs/chitosan NPs,[94] have also been reported for imaging and therapeutic applications. For instance, inspired by the intriguing properties of DNA origami and AuNRs, Du et al.[92] (Figure 6G) designed an optoacoustic imaging (OAI) agent via self-assembly of AuNRs onto DNA-origami nanostructures. The resulting AuNR–DNA-nanostructure hybrid combined the advantages of AuNRs with those of the DNA-origami structure and served as a unique probe and an efficient contrast agent in OAI, and thereby improved the imaging quality with decreased dose. Simultaneously, the NIRresponsive AuNR–DNA-nanostructure hybrid was applied for\nAdv. Healthcare Mater. 2019, 1801158\n1801158 (12 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nPTT, and effectively inhibited tumor regrowth and prolonged the survival of diseased mice."
    }, {
      "heading" : "3.2. Integration of Aptamers with Carbon Nanomaterials",
      "text" : "Graphene oxide, especially nanosized GO (nGO) with a size <100 nm and a narrow distribution, features several unique properties: first, nGO is a super quencher for a wide range of fluorophores via FRET or nonradiative dipole−dipole coupling. Second, the affinity of DNA adsorption on nGO is mediated via π−π stacking and hydrogen bonding, which is strong enough to attain a low background yet weak enough to allow rapid probe release in the presence of target molecules. Third, nGO is readily internalized by living cells with efficient cell membrane permeability. Finally, nGO has low cytotoxicity. Therefore, nGO has emerged as an outstanding platform in the past few years to interface with aptamers for in vivo applications.[95,96]\nIn one example, Tan et al.[97] performed ATP live-cell imaging with greatly improved signal-to-background ratio by using an ATP aptamer molecular beacon functionalized nGO (Figure 7A). To achieve more accurate quantification, a control ssDNA was designed to be released from the GO as it encountered cellular proteins; and the signal from the ssDNA served as an internal reference for calibration and ratiometric quantification. Although the internal standard improved quantification, the nonspecific release of reference ssDNA probe from GO cannot be avoided, introducing certain degree of inaccuracy. To resolve this issue, Liu et al.[98] covalently attached a fluorophore modified ATP aptamer to nGO via an extra amine modification on the aptamer. The resultant nGO ATP probe was used for intracellular ATP detection. Another example was provided by Wang et al.[99] who developed a multiple aptamer/nGO based sensing platform for simultaneous monitoring of ATP and GTP in situ. Recently, Yi et al.[100] (Figure 7B) went a step further and used the deeper penetration depth of two-photon microscopy to develop an aptamer–two photon dye (TP dye)/ GO two-photon excitation fluorescent sensing conjugate for ATP imaging in zebrafish. This approach had advantages of the exceptional quenching capability of GO for the proximate TP dyes and the higher affinity of single-stranded aptamer on GO than the aptamer−target complex, showing great potential for in vivo applications in medical research and clinical diagnostics.\nIn addition to the ATP imaging, aptamer responsive fluorescent nanocomposites containing QDs and GO were further developed by Zhang et al.,[101] and applied to monitor the cellular entry and the drug delivery processes in situ. With the extremely high two-photon absorption cross-section from GO, Pramanik et al.[102] reported a selective two-photon imaging of SK-BR-3 breast tumor cell in second biological transparency windows using 1100 nm wavelength. Chen et al.[103] (Figure 7C) developed a fluorescent aptamer nanosensor to image the activation of cytochrome c. The reported strategy relied on the construction and spatially specific cytosolic delivery of a nanosensor assembled from fluorophore-conjugated DNA aptamers on PEGylated GO. The release of Cyt c in cytosol would bind and dissociated the aptamer from GO, resulting in an increased fluorescence signal. The nanosensor enabled real-time visualization\nof the Cyt c release kinetics and direct identification of the regulators for apoptosis.\nApart from nGO, other types of carbon nanomaterials, including porous GO membranes,[96] CNTs,[104,105] carbon nanodots,[106] graphene QDs,[107] and mesoporous carbon nanospheres,[108] have also been integrated with aptamers for selective cell isolation, imaging, and drug delivery. As an example, using fluorophore-labeled aptamer and single-walled carbon nanotube, Yan et al.[105] developed an activatable aptamer probe for cancer cell (Figure 7D). Through π-stacking and proximityinduced energy transfer, without any target, the probe will be quenched in its free state. Upon binding to cell surface receptors, probe was released and fluorescence signal was activated. In vivo studies further confirmed that specifically activated fluorescence was observed in CCRF-CEM tumors. Compared to “always on” probes, this probe had greatly reduced background signals, thus resulting in much higher contrast in the image. Later, Li et al.[108] reported a mesoporous carbon nanosphere that can deliver drugs to tumors and image tumor biomarkers in real time.\n3.3. Integration of Aptamers with Nucleic Acid Nanostructures\nMolecular engineering of aptamers with nucleic acid nanostructures have been developed in the past decade in a wide range of biomedical studies. For instance, Shi et al.[109] (Figure 8A) reported an activatable aptamer beacon probe (AAP) for targeting membrane proteins of living cancer cells and for imaging cancer tissues in mice. The AAP consisted of three fragments: a cancer-targeted aptamer sequence (A-strand), a poly T linker (T-strand), and a short DNA sequence (C-strand) complementary to a part of the A-strand with a fluorophore and quencher attached to both termini. When the beacon was applied in a CCRF-CEM mouse xenograft model, the tumor-specific antigen PTK1 on the surface of the tumor cells was selectively imaged 60 min after administration, facilitating sensitive detection of early-stage cancer. Later, Zhang et al.[110] designed a controllable aptamer-based self-assembled DNA dendrimer for high affinity targeting, bioimaging and drug delivery. Another smart split aptamer-based activatable theranostic probe was reported as “nanodoctor” for cancer-activated in vivo imaging and in situ drug release (Figure 8B).[111] This nanodoctor exhibited tunable in vivo stability, in which rapid diagnosis with contrastenhanced image was achieved in 5 min.\nRecently, DNA nanoflowers (NFs) were synthesized by co-precipitation of magnesium pyrophosphate and a rolling circle replication (RCR) DNA product. Due to densely packed DNA building blocks, these NFs are resistant to nuclease degradation, denaturation, and dissociation at extremely low concentrations, and hence highly suitable for intracellular imaging and targeted delivery. For instance, Hu et al.[112] reported an aptamer FRET NFs synthesized using RCR for simultaneous imaging of multiple targets using single excitation, in additional to targeted antitumor drug delivery. Also, Wu et al.[113] engineered a switchable aptamer micelle flare by self-assembly of an aptamer-diacyl-lipid chimera, to monitor intracellular ATP. Similarly, Zhang et al.[114] developed a molecular beacon (MB)-based micelle (a-MBM–DOX) for MDR1\nAdv. Healthcare Mater. 2019, 1801158\n1801158 (13 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nthrough the self-assembly of diacyl-lipid–MB (L–MB) and doxorubicin molecules. These a-MBMs were demonstrated to enter cells efficiently and only release the drug after they have bypass the MDR barrier. Hence, this system can have great promise for an all-in-one micelle probe to carry out sequential mRNA imaging and image-guided therapy.\nAnother emerging 3D self-assembled DNA nanostructure is DNA tetrahedron, which has been used for intracellular imaging, cellular imaging and targeted delivery.[115] DNA tetrahedron possesses many interesting properties, including good structural rigidity, excellent biocompatibility, nuclease resistance, and rapid cell entry, contributing to its application for cellular applications. Taking these features, Pei et al.[116] developed an ATP aptamer tetrahedron, for ATP imaging in live cells (Figure 8C). Using the similar method, Xie et al.[117] reported self-assembled DNA tetrahedron molecular beacon for intracellular tumor-related mRNA and ATP detection. Combining the excellent biological properties of DNA nanostructures with low background split aptamers, Zheng et al.[118] developed a FRET-based functional DNA triangularprism for ATP sensing in living cells. Similarly, RNA tetrahedron has been recently reported by Li et al. (Figure 8D),[119] in which EGFR aptamers were placed at the edges of the RNA tetrahedrons with high precision without disrupting the overall structure. These aptamer–RNA tetrahedrons demonstrated tumor-specific enrichment in orthotopic MDA-MB231 tumor-bearing mice after systemic administration. Using the similar strategies, they have also developed a series of aptamer-guided in vivo targeting platform for the treatment of prostate cancer,[120] glioblastoma,[121] gastric cancer,[122] colorectal cancer,[123] and head/neck cancer.[124] Together, several aptamer-integrated RNA nanostructures have demonstrated\nAdv. Healthcare Mater. 2019, 1801158\n1801158 (14 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimAdv. Healthcare Mater. 2019, 1801158\n1801158 (15 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nthe superior capability for selective targeting of diseased tissues over other nanotechnology platforms.\nIn addition to intracellular analysis, another exciting application of aptamer-functionalized nucleic acid nanostructures is toward targeted delivery of therapeutics. For instance, Abnous et al.[125] reported a novel aptamer-based DNA diamond nanostructure for in vivo targeted delivery of epirubicin to cancer cells. Jin et al.[126] used the DNA aptamer-modified oligoguanine quadruplex nanostructures for targeted delivery. The aptamer-tethered oligoguanine nucleotides self-assembled to form Y-shaped DNA structures, which were shown to have strong potential for cells specific drug delivery and improved therapeutic effects. Porciani et al.[127] engineered a cell-internalizing aptamer nanostructure that enables targeted delivery of large functional RNAs in cancer cell lines. This platform exploited cell-internalizing aptamers to accomplish cell-typespecific delivery, along with the fluorescence properties of RNA mimics of GFP as surrogates for other large RNA-based payloads. To further improve the affinity and stability of aptamer-based probes for in vivo applications, Lei et al.[128] designed a novel theranostic strategy of DNA nanotriangle-scaffolded multivalent split activatable aptamer probe (NTri-SAAP), which combines advantages of programmable self-assembly, multivalent effect and target-activatable architecture. The NTriSAAP increased doxorubicin loading capacity by ≈5 times, which further realized a high antitumor efficacy in vivo with 81.95% inhibition but no obvious body weight loss. Another critical challenge for the therapeutic use of aptamer-based DNA nanomaterials is the precise delivery to tumor sites in a highly controlled manner to minimize its side effects. To overcome the challenge, Li et al.[129] constructed a DNA nanorobotic system using DNA origami (Figure 8E). The tubular nanorobot was formed with a foldable origami sheet has thrombin molecules linked to it via DNA aptamers and fasteners capable of binding to nucleolin. In tumor vasculature, the nucleolin interaction could undo the fasteners and thereby release the thrombin to trigger fibrin clot formation, leading to thrombosis and clot formation causing blood vessel occlusion. Bi et al.[130] reported the synthesis of DNA nanohydrogels using a target-catalyzed DNA four-way junction as building units. These DNA nanohydrogels are readily functionalized by incorporating with aptamers, bioimaging agents, and drug loading sites, which thus are served as efficient platform for simultaneously imaging of miRNA and targeted drug delivery for cancer therapy. Other in vivo applications including the monitoring of RNA−RNA hybridization,[131] in vivo aptamer photoregulation,[132] specific imaging of cell-surface glycosylation,[133] and mRNA detection[134] have also been developed based on the integration of aptamers with DNA nanostructures, such as Split-Broccoli assembles,[131] a photolabile oligonucleotide complex,[132] hybridization chain reaction (HCR) nanoassemblies,[133] and DNA nanotube.[134]\nIn addition to the fluorescent imaging, aptamers have been also integrated with other imaging modalities for enhanced in vivo imaging. For instance, photoacoustic (PA) imaging has emerged as a new imaging modality capable of achieving submillimeter resolution at depths up to 7−10 cm. The first DNA aptamer-based PA probe has been recently developed by Zhang et al.,[135] in which a thrombin binding aptamer was hybridized\nwith IRDye 800CW-labeled and IRDye QC-1 quencher-labeled ssDNA to form a DNA duplex structure with efficient contact quenching (Figure 8F). Assembly and disassembly of the DNA complex by the target of interest can inhibit the contact quenching, resulting in a change of the PA signal at its two maximum absorption wavelengths. The aptamer-based PA probe exhibited an enhanced and specific ratiometric change in PA signals toward thrombin injection in vivo, demonstrating the first aptamer-based activatable PA probe for advanced molecular imaging in living mice."
    }, {
      "heading" : "3.4. Integration of Aptamers with Other Nanomaterials",
      "text" : "QDs feature several unique optical properties, including broad absorption spectra, narrow photoluminescence bandwidths, high quantum yield, low photobleaching, and resistance to chemical degradation. The functionalization of QDs with aptamers can be realized via covalently conjugation,[136–140] electrostatic interactions,[141] biotin-streptavidin interactions,[142,143] and aptamer-templated QD synthesis.[144,145] These aptamer–QDs have been increasingly utilized as biological imaging and labeling probes for targeted cell detection and imaging,[136,138,139] drug delivery,[136] gene silencing,[141] and imaging-guided tumor therapy.[137,140] For instance, Zhang et al.[144] offered a strategy to synthesize aptamer-functionalized Zn2+-doped CdTe QDs through a facile one-pot hydrothermal route, and have successfully applied it in active tumor-targeted imaging in vitro and in vivo. Wei et al.[145] went a step further and reported a new type of aptamer templated heterobivalent QD nanoprobes with the ability to target and image two spatially isolated cancer markers present on the cell surface (e.g., nucleolin) and in the cell cytosol (e.g., mRNA). Bypassing endolysosomal sequestration, this type of QD nanoprobes undergo macropinocytosis following the nucleolin targeting and then translocate to the cytosol for mRNA targeting. Recently, aptamer-functionalized NIR Ag2S nanodot has been synthesized through HCR signal amplification,[146] and further combined with immune-magnetic spheres for the efficient isolation and detection of circulating tumor cells (CTCs) in whole blood. To improve the imaging sensitivity of aptamer–QDs, Li et al.[147] further employed HCR for bottom-up construction of aptamer–QDs polymers, which enabled both multidentate targeting and multi-QD-based signal amplification. Another water-soluble Ag2S NIR fluorescent QDs have been synthesized for specific cancer imaging and PTT using a designed aptamer (Apt43) as template.[148] The synthesized Apt43–Ag2S QDs exhibited strong fluorescence emission and absorption in the NIR region and high photothermal conversion capabilities, and have been applied for the in vivo ablation of tumors. In addition, by incorporating two different aptamers into a hybrid micellar QDs, intracellular ATP-activatable aptamer– QDs has been reported by Shen et al.,[149] which enabled dual fluorescence imaging and targeted photodynamic therapy of tumor (Figure 9A).\nAptamer-functionalized UCNPs have also been developed toward targeted bioimaging and delivery,[150–153] intracellular imaging,[154] in vivo sensing,[155] and photodynamic therapy.[156] However, most of the UCNPs are capped with hydrophobic\nAdv. Healthcare Mater. 2019, 1801158\n1801158 (16 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nligands, such as oleylamine, and thereby it remains challenging to prepare biocompatible UCNPs with specific molecular recognition capabilities. To address this issue, Li et al.[157] developed a facile one-step ligand exchange strategy to prepare uniform aptamer-modified UCNPs as versatile bioprobes. The DNA– UCNPs were capable of crossing cell membranes without the need of transfection agents, and their use as agents for targeted imaging of cancer cells has been realized. Later, the same group have also developed a hetero-assembled DNA–AuNP/ UCNP system,[158] which maintains both plasmonic resonance of AuNPs and fluorescent properties of UCNPs, allowing targeted dual-modality imaging of cancer cells using an aptamer. Very recently, Zhao et al.[155] reported a rationally designed, synthetic DNA nanodevice that can detect ATP in living cells and animals in an upconversion luminescence-activatable manner (Figure 9B). The nanodevice consists of a UV light–activatable aptamer probe, and lanthanide-doped UCNPs which act as the nanotransducers to operate the device in response to NIR light. They have demonstrated that the nanodevice not only enables efficient cellular delivery of the aptamer probe into live cells, but also allows the temporal control over its fluorescent sensing activity for ATP by NIR light irradiation in vitro and in vivo. Aptamer–UCNP-based targeted bioimaging and photodynamic therapy have been recently developed by Yuan et al.[159] by using\nAdv. Healthcare Mater. 2019, 1801158\n1801158 (17 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nan aptamer-guided G-Quadruplex DNA carrier and NIR light. Another example came from Fang et al.[160] who utilized the aptamer-conjugated UCNPs for effective isolation and sensitive detection of CTCs assisted by magnetic separation. Another exciting application of aptamer–UCNPs has been reported by Wu et al.,[161] in which profiling cell surface protein-specific glycoforms was realized based on a single excitation-dual LRET (D-LRET) system that consists of UCNPs as a donor and Alexa Fluor 555/660 as two different fluorescence acceptors (Figure 9C).\nIn the past decade, various aptamer-functionalized magnetic nanomaterials have been developed,[162,163] and applied for diverse in vivo applications, including isolation and detection of cancer cells,[164–166] sensing and imaging,[167–172] delivery of therapeutic agents,[173] and cancer imaging and therapy.[174–181] As an example, Westmeyer et al.[167] designed an aptamerbased MRI system that can detect the activity of cell secreted alkaline phosphatase. This method was based on the enzymatic dephosphorylation of AMP to adenosine, which in turn can disrupt a DNA duplex that aggregates MNPs, thereby separating the MNPs and reduce their collective superparamagnetism. In addition, Zhang et al.[168] have developed a core-triple shell structured multifunctional nanoprobe Fe3O4/SiO2/CdSeTe@ ZnS−SiO2/polydopamine with strong fluorescence and a fast magnetic response for specifically recognizing, fluorescently labeling, and magnetically sorting target tumor cells on a microfluidic chip. Li et al.[174] proposed an aptamer-functionalized Fe3O4@Au nanorose with five distinct functions, integrating aptamer-based targeting, MRI, optical imaging, photothermal therapy and chemotherapy into one single probe. Yang et al.[173] (Figure 9D) constructed a smart magnetic nanoaptamer based on the assembly of DNA-templated Fe3O4, hydrophobic dye, HIF-1α and glucose transporter 1 aptamers, and siRNA. The resulting magnetic nanoaptamer can transport siRNA to breast cancer cells or tissues for the attenuation of HIF-1α and ATP, and thereby inhibits the growth of cancer cells in vivo.\nIn addition to the above-mentioned aptamer–nanomaterial systems, other types of aptamer-based nanomaterials, such as liposome,[182–186] silica nanomaterials,[187–194] polymer nanomaterials,[195–198] MOFs,[199] dendrimers,[200,201] micellar nanoparticles,[202,203] gadolinium oxide nanoparticles,[204,205] calcium carbonate nanostructure,[206] polydopamine nanospheres,[207,208] MoS2 nanoplates,[209] lipid-based nanobubbles,[210] dipeptide nanoparticles,[211] aggregation-induced emission organic dots,[212] and MnO2 nanosheet,[213] have been engineered as promising candidates toward in vivo applications in diverse areas. Based on these studies, we summarize the representative reports focusing on aptamers integrated with other nanomaterials, as shown in Table 2."
    }, {
      "heading" : "4. Molecular Engineering of Aptazyme-Based Nanomaterials toward In Vivo Applications",
      "text" : "Aptazymes are ligand-activate self-cleaving ribozymes that contain both an aptamer domain and a ribozyme domain, which can readily convert the binding signals to more distinct signals of enzyme activities (Figure 10A),[214] such as self-cleavage or ligase.[215] In the absence of the target ligand, the enzymatic\nactivity of the catalytic element cannot be expressed due to inappropriate structural folding. However, the introduction of the target ligand can induce the adaptive folding of the aptamer domain, leading to the structural formation of the catalytic domain and subsequently its activation. Soukup and Breaker were the pioneers in coupling catalytic domains to aptameric recognition domains,[216] in which the binding of the target ligand to the aptamer induces the catalytic event (ligation or cleavage). Based on this strategy, aptazymes are able to directly transduce molecular recognition into a quantitative catalytic event. Taking advantages of highly specific recognition property of aptamers and signal amplification property of NAEs via multiple-turnover reactions, aptazymes have demonstrated their great promise in many in vitro applications.[217–219]\nHowever, in contrast to the broad in vivo applications of NAEs and aptamers, there are considerably less studies on aptazymes for similar applications.[211] This difference was mainly due to two reasons from both fundamental and technical aspect. First, most aptazyme sensors are developed by artificial design using known NAEs and aptamers rather than by more efficient combinatorial selection strategies, and this fundamental limitation thereby results in extensive trial-anderror and optimization procedures when identifying an aptazyme sensor with target-dependent response. Second, many of these design strategies for aptazymes often involve changes in the active sites or binding arms of FNAs to introduce aptamer sequences into NAEs. Such strategies have been successfully applied for target detection, but the insertion of aptamers may interfere the activity of the NAEs and make it difficult to apply the same design approach rationally to other NAEs and aptamer pairs, because of the dramatically different properties of each NAEs and aptamer. So far, unfortunately, few aptazymes have been integrated with nanomaterials toward in vivo applications."
    }, {
      "heading" : "4.1. Integration of Aptazymes with Noble Metal Nanomaterials",
      "text" : "The integration of noble metal nanomaterials with aptazymes for amplified molecular probing in living cells was first reported by Yang et al. (Figure 10B),[220] where they combined gold nanoparticles with a well-characterized ATP-specific aptazyme strand, composed of Mg2+-dependent 10−23 DNAzyme and ATP aptamer. The target molecule can activate the aptazyme and then cleave and release the fluorophore-labeled substrate strands from the AuNP, resulting in fluorescence enhancement. They demonstrated that the aptazyme–AuNP can readily enter living cells and realize intracellular ATP detection at physiological concentration of Mg2+, with no additional Mg2+ required."
    }, {
      "heading" : "4.2. Integration of Aptazymes with Nucleic Acid Nanostructures",
      "text" : "Aptazymes-embedded DNA nanostructures have been developed for various in vivo applications.[221,222] For instance, Ogawa and Maeda reported aptazyme-based riboswitches based on a theophylline aptamer and an antiribosome binding site (RBS) sequence.[223] They integrated the aptazyme with a RBS and a complementary anti-RBS, resulted in an artificial\nAdv. Healthcare Mater. 2019, 1801158\n1801158 (18 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nribozyme-based riboswitch. In this way, the ligand-dependent hammerhead ribozyme (HHR) mediated cleavage reaction could remove the anti-RBS domain from the transcript, releasing the RBS and thus enabling translation of the mRNA both in vitro and in vivo. Later, Wieland and Hartig presented an improved hammerhead aptazyme design that enables ribozymes to act as artificial riboswitches in bacteria.[224] In other cases, it was demonstrated that aptazymes can also be used to control the activity of tRNAs,[225] regulation of miRNAs,[226] and 16S Ribosomal RNA in bacteria.[222] Later, aptazymes have been demonstrated for diverse applications, including construction of synthetic gene networks in yeast,[227] and regulation of transgene expression,[228] or virus replication in mammalian cell culture.[229] Recently, rational design of aptazyme riboswitches for efficient control of gene expression in mammalian cells was developed by Zhong et al. (Figure 10C).[230] These aptazymes efficiently regulated adeno-associated virus (AAV)vectored transgene expression in cultured mammalian cells and mice, highlighting one application of these broadly usable regulatory switches. Additionally, combining with CRISPR technologies, aptazyme-based nanomaterials have showed the ability to improve the dynamically control of gene expression. For example, Tang et al. embedded self-cleaving catalytic RNA aptazymes in the sgRNA (Figure 10D),[231] which block the sgRNA spacer sequence until exposure to a ligand. These aptazymeembedded guide RNAs exhibited three unique features: small molecule-controlled nuclease-mediated genome editing, small molecule-controlled base editing, and small moleculedependent transcriptional activation in mammalian cells. 5. Summary and Perspectives In summary, we have provided a review of exciting advancements of molecular engineering of nanomaterials with FNAs,\nAdv. Healthcare Mater. 2019, 1801158\n1801158 (19 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nincluding NAEs, aptamers, and aptazymes. These FNA nanomaterials have shown several unique features that make them as promising candidates toward diverse in vivo applications. For example, different therapeutic agents, such as chemotherapeutic drugs, photosensitizers, and siRNA, have been integrated with aptamers for targeted cancer therapy based on different therapeutic strategies.[232] In addition, FNA-based theranostic agents with both imaging and therapeutic functions have also been developed to increase diagnosis accuracy and therapy efficiency. Finally, the combination of different nanomaterials into hybrid nanomaterials yielded new nanocomposites with multifunctionalities for various in vivo applications. Another emerging development for this field is that researchers are now capable of encoding and self-assembling nanostructures inside live cells.[233] This opens up the possibility of encoding new FNA nanomaterials inside cells and even whole organisms, providing a new direction for the development of efficient targeted diagnostics and therapeutics in vivo. Despite such remarkable progress in engineering FNA nanomaterials toward in vivo applications, there remains several challenges limiting their clinical applications. First, most of the reported NAEs and aptamers are selected and applied in in vitro studies. The in vivo behaviors of these FNAs may be far more complicated than our present knowledge, and it is of high probability that FNAs selected in vitro lose their functionalities to some extent toward their targets in living systems. Therefore, an innovation of SELEX protocols for FNAs with more desired performance under in vivo applications is needed. Second, for intracellular or in vivo imaging, rationally designed FNA nanomaterials can greatly increase the\nAdv. Healthcare Mater. 2019, 1801158\n1801158 (20 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nsensitivity and specificity for biomolecular recognition because of the well-controlled probe density, orientation, and surface passivation.[234] In this way, these FNA nanomaterials could provide a versatile and efficient platform for imaging of various targets in vivo. In addition, the development of NIR-emitting FNA nanomaterials is another avenue for in vivo biosensing and imaging since the tissues, blood, and water exhibit minimal absorption and autofluorescence in the NIR region. However, it remains a challenge to develop an NIR-emitting nanomaterial with high fluorescent quantum yield, and therefore innovative approaches are needed to facilitate the improvement of fluorescent quantum yields in the NIR range. Meanwhile, the biocompatibility of the FNA nanomaterials is also important to improve the precision and accuracy for the detection of biological targets in complex sample matrices toward in vivo applications. The integration of FNAs with nanomaterials may introduce the biosafety risk, such as toxicity and inflammation induced by nanomaterials, which requires further studies before the translation of FNA-based nanomaterials into clinical applications.\nFinally, for therapeutic purpose, the cellular uptake, endosomal escape, and in vivo stability of FNA nanomaterials still need to be optimized. We anticipate that new designs based on these foundations will be developed to further improve sensing, imaging, and drug delivery. Another challenge is to improve the delivery of FNA nanomaterials in a precisely controlled manner to meet the needs of a given in vivo application, and additionally direct the FNA nanomaterials to the subcellular molecular imaging for more efficient diagnostics and therapeutics in vivo. Overcoming these challenges would further broaden the scope of in vivo applications of FNA nanomaterials and potentially facilitate their translation into clinical applications."
    }, {
      "heading" : "Acknowledgements",
      "text" : "The Lu group research described in this review was supported by US National Institute of Health (GM124316 and MH110975). GlucoSentient R&D related to this review was supported by NIH (MH111337-01)."
    }, {
      "heading" : "Conflict of Interest",
      "text" : "The authors are affiliated with GlucoSentient, Inc., a small startup company based in Champaign, IL (USA)."
    }, {
      "heading" : "Keywords",
      "text" : "aptamers, DNAzyme, functional nucleic acid, in vivo applications, nanomaterials\nReceived: September 17, 2018 Revised: January 14, 2019\nPublished online:\n[1] J. J. Zhang, F. F. Cheng, J. J. Li, J. J. Zhu, Y. Lu, Nano Today 2016, 11, 309. [2] A. Samanta, I. L. Medintz, Nanoscale 2016, 8, 9037.\n[3] A. J. Sivaram, A. Wardiana, C. B. Howard, S. M. Mahler, K. J. Thurecht, Adv. Healthcare Mater. 2018, 7, 1700607. [4] C. Angell, M. X. Kai, S. B. Xie, X. Y. Dong, Y. Chen, Adv. Healthcare Mater. 2018, 7, 1701189. [5] J. Kim, D. Jang, H. Park, S. Jung, D. H. Kim, W. J. Kim, Adv. Mater. 2018, 30, 1707351. [6] J. W. Liu, Z. H. Cao, Y. Lu, Chem. Rev. 2009, 109, 1948. [7] J. Li, F. Li, H. Pei, L. H. Wang, Q. Huang, C. H. Fan, in Advanced\nTheranostic Materials (Eds: A. Tiwari, H. K. Patra, J. Choi), Wiley-VCH, Weinheim, Germany 2015, Ch. 4, https://doi. org/10.1002/9781118998922.ch4. [8] H. Pei, X. L. Zuo, D. Zhu, Q. Huang, C. H. Fan, Acc. Chem. Res. 2014, 47, 550.\n[9] H. E. Ihms, Y. Lu, Methods Mol. Biol. 2012, 848, 297. [10] H. M. Meng, H. Liu, H. L. Kuai, R. Z. Peng, L. T. Mo, X. B. Zhang,\nChem. Soc. Rev. 2016, 45, 2583. [11] Z. D. Wang, Y. Lu, J. Mater. Chem. 2009, 19, 1788. [12] H. Liang, X. B. Zhang, Y. F. Lv, L. Gong, R. W. Wang, X. Y. Zhu,\nR. H. Yang, W. H. Tan, Acc. Chem. Res. 2014, 47, 1891. [13] J. J. Zhang, Catalysts 2018, 8, 550. [14] J. H. Zhou, J. Rossi, Nat. Rev. Drug Discovery 2017, 16, 181. [15] Q. Q. Hu, S. Wang, L. H. Wang, H. Z. Gu, C. H. Fan, Adv.\nHealthcare Mater. 2018, 7, 1701153. [16] S. F. Torabi, Y. Lu, Curr. Opin. Biotechnol. 2014, 28, 88. [17] X. H. Zhao, H. M. Meng, L. Gong, L. P. Qiu, X. B. Zhang,\nW. H. Tan, Chinese J. Anal. Chem. 2015, 43, 1611. [18] K. Yehl, J. P. Joshi, B. L. Greene, R. B. Dyer, R. Nahta, K. Salaita,\nACS Nano 2012, 6, 9150. [19] I. Somasuntharam, K. Yehl, S. L. Carroll, J. T. Maxwell,\nM. D. Martinez, P. L. Che, M. E. Brown, K. Salaita, M. E. Davis, Biomaterials 2016, 83, 12. [20] Z. M. He, P. H. Zhang, X. Li, J. R. Zhang, J. J. Zhu, Sci. Rep. 2016, 6, 22737. [21] P. Wu, K. Hwang, T. Lan, Y. Lu, J. Am. Chem. Soc. 2013, 135, 5254. [22] L. Li, J. Feng, Y. Fan, B. Tang, Anal. Chem. 2015, 87, 4829. [23] C. Yang, X. Yin, S. Y. Huan, L. Chen, X. X. Hu, M. Y. Xiong,\nK. Chen, X. B. Zhang, Anal. Chem. 2018, 90, 3118. [24] K. Hwang, P. W. Wu, T. Kim, L. Lei, S. L. Tian, Y. X. Wang, Y. Lu,\nAngew. Chem., Int. Ed. 2014, 53, 13798. [25] X. Wang, M. Feng, L. Xiao, A. Tong, Y. Xiang, ACS Chem. Biol.\n2016, 11, 444. [26] W. Wang, N. S. R. Satyavolu, Z. Wu, J. R. Zhang, J. J. Zhu, Y. Lu,\nAngew. Chem., Int. Ed. 2017, 56, 6798. [27] P. Zhang, Z. He, C. Wang, J. Chen, J. Zhao, X. Zhu, C. Z. Li,\nQ. Min, J. J. Zhu, ACS Nano 2015, 9, 789. [28] H. Peng, X. F. Li, H. Zhang, X. C. Le, Nat. Commun. 2017, 8,\n14378. [29] Y. Yang, J. Huang, X. Yang, X. He, K. Quan, N. Xie, M. Ou,\nK. Wang, Anal. Chem. 2017, 89, 5850. [30] J. Liu, M. Cui, H. Zhou, W. Yang, ACS Sens. 2017, 2, 1847. [31] Y. Wu, J. Huang, X. Yang, Y. Yang, K. Quan, N. Xie, J. Li, C. Ma,\nK. Wang, Anal. Chem. 2017, 89, 8377. [32] F. Li, T. G. Cha, J. Pan, A. Ozcelikkale, B. Han, J. H. Choi,\nChemBioChem. 2016, 17, 1138. [33] H. Si, R. Sheng, Q. Li, J. Feng, L. Li, B. Tang, Anal. Chem. 2018, 90,\n8785. [34] F. L. Gao, J. Wu, Y. Yao, Y. Zhang, X. J. Liao, D. Q. Geng,\nD. Q. Tang, RSC Adv. 2018, 8, 28161. [35] Z. H. Li, J. Wang, Y. X. Li, X. W. Liu, Q. Yuan, Mater. Chem. Front.\n2018, 2, 423. [36] W. Zhou, W. Liang, D. Li, R. Yuan, Y. Xiang, Biosens. Bioelectron.\n2016, 85, 573. [37] Z. Wu, H. Fan, N. S. R. Satyavolu, W. Wang, R. Lake, J. H. Jiang,\nY. Lu, Angew. Chem., Int. Ed. 2017, 56, 8721.\nAdv. Healthcare Mater. 2019, 1801158\n1801158 (21 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\n[38] A. Belter, K. Rolle, M. Piwecka, A. Fedoruk-Wyszomirska, M. Z. Naskret-Barciszewska, J. Barciszewski, Sci. Rep. 2016, 6, 24516. [39] Y. Jin, Z. H. Li, H. F. Liu, S. Z. Chen, F. Wang, L. Wang, N. Li, K. Ge, X. J. Yang, X. J. Liang, J. C. Zhang, NPG Asia Mater. 2017, 9, e365. [40] X. Chen, J. Zhao, T. Chen, T. Gao, X. Zhu, G. Li, Theranostics 2018, 8, 1075. [41] Y. Jin, L. N. Liang, X. J. Sun, G. S. Yu, S. Z. Chen, S. T. Shi, H. F. Liu, Z. H. Li, K. Ge, D. D. Liu, X. J. Yang, J. C. Zhang, NPG Asia Mater. 2018, 10, 373. [42] D. Li, F. Mo, J. Wu, Y. Huang, H. Zhou, S. Ding, W. Chen, Sci. Rep. 2018, 8, 10196. [43] S. R. Ryoo, H. Jang, K. S. Kim, B. Lee, K. B. Kim, Y. K. Kim, W. S. Yeo, Y. Lee, D. E. Kim, D. H. Min, Biomaterials 2012, 33, 2754. [44] S. F. Bakshi, N. Guz, A. Zakharchenko, H. Deng, A. V. Tumanov, C. D. Woodworth, S. Minko, D. M. Kolpashchikov, E. Katz, Nanoscale 2018, 10, 1356. [45] H. Fan, Z. Zhao, G. Yan, X. Zhang, C. Yang, H. Meng, Z. Chen, H. Liu, W. Tan, Angew. Chem., Int. Ed. 2015, 54, 4801. [46] F. Chen, M. Bai, K. Cao, Y. Zhao, J. Wei, Y. X. Zhao, Adv. Funct. Mater. 2017, 27, 1702748. [47] F. Chen, M. Bai, K. Cao, Y. Zhao, X. W. Cao, J. Wei, N. Wu, J. Li, L. H. Wang, C. H. Fan, Y. X. Zhao, ACS Nano 2017, 11, 11908. [48] N. Li, Y. Li, X. Gao, Z. Yu, W. Pan, B. Tang, Chem. Commun. 2017, 53, 4962. [49] L. Zhang, H. Y. Huang, N. Xu, Q. H. Yin, J. Mater. Chem. B 2014, 2, 4935. [50] J. T. Yi, T. T. Chen, J. Huo, X. Chu, Anal. Chem. 2017, 89, 12351. [51] Z. L. Yang, K. Y. Loh, Y. T. Chu, R. P. Feng, N. S. R. Satyavolu,\nM. Y. Xiong, S. M. N. Huynh, K. Hwang, L. L. Li, H. Xing, X. B. Zhang, Y. R. Chelma, M. Gruebele, Y. Lu, J. Am. Chem. Soc. 2018, 140, 17656. [52] S. F. Torabi, P. Wu, C. E. McGhee, L. Chen, K. Hwang, N. Zheng, J. Cheng, Y. Lu, Proc. Natl. Acad. Sci. USA 2015, 112, 5903. [53] H. Xing, N. Y. Wong, Y. Xiang, Y. Lu, Curr. Opin. Chem. Biol. 2012, 16, 429. [54] Y. H. Lao, K. K. L. Phua, K. W. Leong, ACS Nano 2015, 9, 2235. [55] J. T. Dong, M. P. Zhao, TrAC, Trends Anal. Chem. 2016, 80, 190. [56] C. C. Wang, S. M. Wu, H. W. Li, H. T. Chang, Chem Bio Chem.\n2016, 17, 1052. [57] Y. F. Huang, H. T. Chang, W. H. Tan, Anal. Chem. 2008, 80, 567. [58] D. J. Javier, N. Nitin, M. Levy, A. Ellington, R. Richards-Kortum,\nBioconjugate Chem. 2008, 19, 1309. [59] D. Kim, Y. Y. Jeong, S. Jon, ACS Nano 2010, 4, 3689. [60] J. Zheng, G. Zhu, Y. Li, C. Li, M. You, T. Chen, E. Song, R. Yang,\nW. Tan, ACS Nano 2013, 7, 6545. [61] S. M. Ryou, J. H. Yeom, H. J. Kang, M. Won, J. S. Kim, B. Lee,\nM. J. Seong, N. C. Ha, J. Bae, K. Lee, J. Controlled Release 2014, 196, 287. [62] Z. Chen, L. Zhang, Y. He, Y. Li, ACS Appl. Mater. Interfaces 2014, 6, 14196. [63] F. Jin, J. Zheng, C. Liu, S. Yang, Y. Li, J. Li, Y. Lian, R. Yang, Analyst 2014, 139, 3714. [64] S. E. Lee, Q. Chen, R. Bhat, S. Petkiewicz, J. M. Smith, V. E. Ferry, A. L. Correia, A. P. Alivisatos, M. J. Bissell, Nano Lett. 2015, 15, 4564. [65] C. H. Li, T. R. Kuo, H. J. Su, W. Y. Lai, P. C. Yang, J. S. Chen, D. Y. Wang, Y. C. Wu, C. C. Chen, Sci. Rep. 2015, 5, 15675. [66] F. J. Nicholls, M. W. Rotz, H. Ghuman, K. W. MacRenaris, T. J. Meade, M. Modo, Biomaterials 2016, 77, 291. [67] Y. Yang, J. Huang, X. Yang, K. Quan, N. Xie, M. Ou, J. Tang, K. Wang, Chem. Commun. 2016, 52, 11386.\n[68] L. Chen, J. Chao, X. Qu, H. Zhang, D. Zhu, S. Su, A. Aldalbahi, L. Wang, H. Pei, ACS Appl. Mater. Interfaces 2017, 9, 8014. [69] L. Tang, G. Yu, L. Tan, M. Li, X. Deng, J. Liu, A. Li, X. Lai, J. Hu, Sci. Rep. 2017, 7, 8553. [70] D. Zhang, A. Zheng, J. Li, M. Wu, L. Wu, Z. Wei, N. Liao, X. Zhang, Z. Cai, H. Yang, G. Liu, X. Liu, J. Liu, Theranostics 2017, 7, 164. [71] H. Si, L. Wang, Q. Li, X. Li, L. Li, B. Tang, Chem. Commun. 2018, 54, 8277. [72] J. Tang, C. Huang, J. Shu, J. Zheng, D. Ma, J. Li, R. Yang, Anal. Chem. 2018, 90, 5865. [73] T. Demeritte, Z. Fan, S. S. Sinha, J. Duan, R. Pachter, P. C. Ray, Chem. – Eur. J. 2014, 20, 1017. [74] W. Wang, C. Chen, X. Li, S. Wang, X. Luo, Chem. Commun. 2015, 51, 9109. [75] H. Jo, H. Youn, S. Lee, C. Ban, J. Mater. Chem. B 2014, 2, 4862. [76] Y. Li, X. L. Wang, L. Gao, P. Hu, L. C. Jian, T. Y. Ren, R. Fu,\nD. W. Yang, X. H. Jiang, J. Mater. Sci. 2018, 53, 14138. [77] M. P. Melancon, M. Zhou, R. Zhang, C. Xiong, P. Allen, X. Wen,\nQ. Huang, M. Wallace, J. N. Myers, R. J. Stafford, D. Liang, A. D. Ellington, C. Li, ACS Nano 2014, 8, 4530. [78] D. Chen, B. Li, S. Cai, P. Wang, S. Peng, Y. Sheng, Y. He, Y. Gu, H. Chen, Biomaterials 2016, 100, 1. [79] L. Q. Chen, S. J. Xiao, L. Peng, T. Wu, J. Ling, Y. F. Li, C. Z. Huang, J. Phys. Chem. B 2010, 114, 3655. [80] J. L. Li, X. Q. Zhong, F. F. Cheng, J. R. Zhang, L. P. Jiang, J. J. Zhu, Anal. Chem. 2012, 84, 4140. [81] J. J. Li, W. J. Wang, D. F. Sun, J. N. Chen, P. H. Zhang, J. R. Zhang, Q. H. Min, J. J. Zhu, Chem. Sci. 2013, 4, 3514. [82] J. J. Li, J. You, Y. P. Zhuang, C. P. Han, J. F. Hu, A. Wang, K. Xu, J. J. Zhu, Chem. Commun. 2014, 50, 7107. [83] G. M. Han, Z. Z. Jia, Y. J. Zhu, J. J. Jiao, D. M. Kong, X. Z. Feng, Anal. Chem. 2016, 88, 10800. [84] G. L. Liu, J. J. Lo, D. Q. Feng, J. J. Zhu, W. Wang, Anal. Chem. 2017, 89, 1002. [85] J. J. Yin, X. X. He, K. M. Wang, F. Z. Xu, J. F. Shangguan, D. G. He, H. Shi, Anal. Chem. 2013, 85, 12011. [86] H. Li, H. T. Hu, Y. J. Zhao, X. Chen, W. Li, W. B. Qiang, D. K. Xu, Anal. Chem. 2015, 87, 3736. [87] H. Li, H. T. Hu, D. K. Xu, Anal. Chem. 2015, 87, 3826. [88] H. Shi, X. S. Ye, X. X. He, K. M. Wang, W. S. Cui, D. G. He, D. Li,\nX. K. Jia, Nanoscale 2014, 6, 8754. [89] X. S. Ye, H. Shi, X. X. He, Y. R. Yu, D. G. He, J. L. Tang, Y. L. Lei,\nK. M. Wang, Nanoscale 2016, 8, 2260. [90] S. Q. Hu, B. Y. Ye, H. L. Tang, F. Wu, X. Y. Yi, T. T. Yi, D. H. Wu,\nL. Wu, J. X. Wang, J. Mater. Chem. B 2018, 6, 1187. [91] Y. J. Zhu, W. J. Li, Z. Y. Hong, A. N. Tang, D. M. Kong, J. Mater.\nChem. B 2017, 5, 9229. [92] Y. Du, Q. Jiang, N. Beziere, L. L. Song, Q. Zhang, D. Peng,\nC. W. Chi, X. Yang, H. B. Guo, G. Diot, V. Ntziachristos, B. Q. Ding, J. Tian, Adv. Mater. 2016, 28, 10000. [93] W. Y. Mu, X. X. Xiao, T. T. Chen, Q. Y. Chen, J. Mater. Chem. B 2016, 4, 5284. [94] X. L. Guo, Q. F. Zhuang, T. J. Ji, Y. L. Zhang, C. J. Li, Y. Q. Wang, H. Li, H. Y. Jia, Y. Liu, L. B. Du, Carbohydr. Polym. 2018, 195, 311. [95] R. C. Huang, W. J. Chiu, I. P. J. Lai, C. C. Huang, Sci. Rep. 2015, 5, 10292. [96] B. P. V. Nellore, R. Kanchanapally, A. Pramanik, S. S. Sinha, S. R. Chavva, A. Hamme, P. C. Ray, Bioconjugate Chem. 2015, 26, 235. [97] X. H. Tan, T. Chen, X. L. Xiong, Y. Mao, G. Z. Zhu, E. Yasun, C. M. Li, Z. Zhu, W. H. Tan, Anal. Chem. 2012, 84, 8622. [98] Z. B. Liu, S. S. Chen, B. W. Liu, J. P. Wu, Y. B. Zhou, L. Y. He, J. S. Ding, J. W. Liu, Anal. Chem. 2014, 86, 12229. [99] Y. Wang, L. H. Tang, Z. H. Li, Y. H. Lin, J. H. Li, Nat. Protoc. 2014, 9, 1944.\nAdv. Healthcare Mater. 2019, 1801158\n1801158 (22 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\n[100] M. Yi, S. Yang, Z. Y. Peng, C. H. Liu, J. S. Li, W. W. Zhong, R. H. Yang, W. H. Tan, Anal. Chem. 2014, 86, 3548. [101] L. Zhang, S. J. Xiao, L. L. Zheng, Y. F. Li, C. Z. Huang, J. Mater. Chem. B 2014, 2, 8558. [102] A. Pramanik, S. R. Chavva, Z. Fan, S. S. Sinha, B. Priya, V. Nellore, P. C. Ray, J. Phys. Chem. Lett. 2014, 5, 2150. [103] T. T. Chen, X. Tian, C. L. Liu, J. Ge, X. Chu, Y. F. Li, J. Am. Chem. Soc. 2015, 137, 982. [104] S. A. Khan, R. Kanchanapally, Z. Fan, L. Beqa, A. K. Singh, D. Senapati, P. C. Ray, Chem. Commun. 2012, 48, 6711. [105] L. A. Yan, H. Shi, X. X. He, K. M. Wang, J. L. Tang, M. A. Chen, X. S. Ye, F. Z. Xu, Y. L. Lei, Anal. Chem. 2014, 86, 9271. [106] C. H. Lee, R. Rajendran, M. S. Jeong, H. Y. Ko, J. Y. Joo, S. Cho, Y. W. Chang, S. Kim, Chem. Commun. 2013, 49, 6543. [107] X. J. Wang, X. Sun, H. He, H. Yang, J. Lao, Y. Z. Song, Y. Q. Xia, H. Xu, X. D. Zhang, F. Huang, J. Mater. Chem. B 2015, 3, 3583. [108] C. Y. Li, M. Qian, S. S. Wang, H. L. Jiang, Y. L. Du, J. X. Wang, W. Y. Lu, N. Murthy, R. Q. Huang, Theranostics 2017, 7, 3319. [109] H. Shi, X. X. He, K. M. Wang, X. Wu, X. S. Ye, Q. P. Guo, W. H. Tan, Z. H. Qing, X. H. Yang, B. Zhou, Proc. Natl. Acad. Sci. USA 2011, 108, 3900. [110] H. Zhang, Y. Ma, Y. Xie, Y. An, Y. Huang, Z. Zhu, C. J. Yang, Sci. Rep. 2015, 5, 10099. [111] Y. L. Lei, J. L. Tang, H. Shi, X. S. Ye, X. X. He, F. Z. Xu, L. A. Yan, Z. Z. Qiao, K. M. Wang, Anal. Chem. 2016, 88, 11699. [112] R. Hu, X. B. Zhang, Z. L. Zhao, G. Z. Zhu, T. Chen, T. Fu, W. H. Tan, Angew. Chem., Int. Ed. 2014, 53, 5821. [113] C. C. Wu, T. Chen, D. Han, M. X. You, L. Peng, S. Cansiz, G. Z. Zhu, C. M. Li, X. L. Xiong, E. Jimenez, C. J. Yang, W. H. Tan, ACS Nano 2013, 7, 5724. [114] R. L. Zhang, S. Gao, Z. L. Wang, D. Han, L. Liu, Q. J. Ma, W. H. Tan, J. Tian, X. Y. Chen, Adv. Funct. Mater. 2017, 27, 1701027. [115] N. L. Xie, S. Y. Liu, X. H. Yang, X. X. He, J. Huang, K. M. Wang, Analyst 2017, 142, 3322. [116] H. Pei, L. Liang, G. B. Yao, J. Li, Q. Huang, C. H. Fan, Angew. Chem., Int. Ed. 2012, 51, 9020. [117] N. L. Xie, J. Huang, X. H. Yang, Y. J. Yang, K. Quan, M. Ou, H. M. Fang, K. M. Wang, ACS Sens. 2016, 1, 1445. [118] X. F. Zheng, R. Z. Peng, X. Jiang, Y. Y. Wang, S. Xu, G. L. Ke, T. Fu, Q. L. Liu, S. Y. Huan, X. B. Zhang, Anal. Chem. 2017, 89, 10941. [119] H. Li, K. M. Zhang, F. M. Pi, S. J. Guo, L. Shlyakhtenko, W. Chiu, D. Shu, P. X. Guo, Adv. Mater. 2016, 28, 7501. [120] D. W. Binzel, Y. Shu, H. Li, M. Y. Sun, Q. S. Zhang, D. Shu, B. Guo, P. X. Guo, Mol. Ther. 2016, 24, 1267. [121] T. J. Lee, F. Haque, D. Shu, J. Y. Yoo, H. Li, R. A. Yokel, C. Horbinski, T. H. Kim, S. H. Kim, C. H. Kwon, I. Nakano, B. Kaur, P. X. Guo, C. M. Croce, OncoTarget 2015, 6, 14766. [122] D. X. Cui, C. L. Zhang, B. Liu, Y. Shu, T. Du, D. Shu, K. Wang, F. P. Dai, Y. L. Liu, C. Li, F. Pan, Y. M. Yang, J. Ni, H. Li, B. Brand-Saberi, P. X. Guo, Sci. Rep. 2015, 5, 10726. [123] P. Rychahou, F. Haque, Y. Shu, Y. Zaytseva, H. L. Weiss, E. Y. Lee, W. Mustain, J. Valentino, P. X. Guo, B. M. Evers, ACS Nano 2015, 9, 1108. [124] Y. Shu, F. Haque, D. Shu, W. Li, Z. Q. Zhu, M. Kotb, Y. Lyubchenko, P. X. Guo, RNA 2013, 19, 767. [125] K. Abnous, N. M. Danesh, M. Ramezani, P. Lavaee, S. H. Jalalian, R. Yazdian-Robati, A. S. Emrani, K. Y. Hassanabad, S. M. Taghdisi, RSC Adv. 2017, 7, 15181. [126] H. Jin, M. G. Kim, S. B. Ko, D. H. Kim, B. J. Lee, R. B. Macgregor, G. Shim, Y. K. Oh, Nanoscale 2018, 10, 7511. [127] D. Porciani, L. N. Cardwell, K. D. Tawiah, K. K. Alam, M. J. Lange, M. A. Daniels, D. H. Burke, Nat. Commun. 2018, 9, 2283. [128] Y. L. Lei, Z. Z. Qiao, J. L. Tang, X. X. He, H. Shi, X. S. Ye, L. Yan, D. G. He, K. M. Wang, Theranostics 2018, 8, 4062. [129] S. P. Li, Q. Jiang, S. L. Liu, Y. L. Zhang, Y. H. Tian, C. Song, J. Wang, Y. G. Zou, G. J. Anderson, J. Y. Han, Y. Chang, Y. Liu, C. Zhang, L. Chen, G. B. Zhou, G. J. Nie, H. Yan, B. Q. Ding, Y. L. Zhao, Nat. Biotechnol. 2018, 36, 258. [130] S. Bi, B. Xiu, J. Y. Ye, Y. Dong, ACS Appl. Mater. Interfaces 2015, 7, 23310. [131] K. K. Alam, K. D. Tawiah, M. F. Lichte, D. Porciani, D. H. Burke, ACS Synth. Biol. 2017, 6, 1710. [132] L. L. Li, R. Tong, H. H. Chu, W. P. Wang, R. Langer, D. S. Kohane, Proc. Natl. Acad. Sci. USA 2014, 111, 17099. [133] B. Y. Yuan, Y. Y. Chen, Y. Q. Sun, Q. P. Guo, J. Huang, J. B. Liu, X. X. Meng, X. H. Yang, X. H. Wen, Z. H. Li, L. Li, K. M. Wang, Anal. Chem. 2018, 90, 6131. [134] X. T. Ji, H. Y. Lv, J. Y. Guo, C. F. Ding, X. L. Luo, Chem.–Eur. J. 2018, 24, 10171. [135] J. J. Zhang, L. P. Smaga, N. S. R. Satyavolu, J. Chan, Y. Lu, J. Am. Chem. Soc. 2017, 139, 17225. [136] V. Bagalkot, L. Zhang, E. Levy-Nissenbaum, S. Jon, P. W. Kantoff, R. Langer, O. C. Farokhzad, Nano Lett. 2007, 7, 3065. [137] R. Savla, O. Taratula, O. Garbuzenko, T. Minko, J. Controlled Release 2011, 153, 16. [138] D. H. Hu, P. F. Zhang, P. Gong, S. H. Lian, Y. Y. Lu, D. Y. Gao, L. T. Cai, Nanoscale 2011, 3, 4724. [139] G. F. Jie, Y. B. Zhao, Y. Q. Qin, Chem. – Asian J. 2014, 9, 1261. [140] W. Du, Y. Yuan, L. Wang, Y. S. Cui, H. Wang, H. Q. Xu, G. L. Liang, Bioconjugate Chem. 2015, 26, 2571. [141] V. Bagalkot, X. H. Gao, ACS Nano 2011, 5, 8131. [142] T. C. Chu, F. Shieh, L. A. Lavery, M. Levy, R. Richards-Kortum, B. A. Korgel, A. D. Ellington, Biosens. Bioelectron. 2006, 21, 1859. [143] L. Q. Chen, S. J. Xiao, P. P. Hu, L. Peng, J. Ma, L. F. Luo, Y. F. Li, C. Z. Huang, Anal. Chem. 2012, 84, 3099. [144] C. L. Zhang, X. H. Ji, Y. Zhang, G. H. Zhou, X. L. Ke, H. Z. Wang, P. Tinnefeld, Z. K. He, Anal. Chem. 2013, 85, 5843. [145] W. Wei, X. W. He, N. Ma, Angew. Chem., Int. Ed. 2014, 53, 5573. [146] C. P. Ding, C. L. Zhang, X. Y. Yin, X. Y. Cao, M. F. Cai, Y. Z. Xian, Anal. Chem. 2018, 90, 6702. [147] Z. Li, X. W. He, X. C. Luo, L. Wang, N. Ma, Anal. Chem. 2016, 88, 9355. [148] J. W. Gao, C. L. Wu, D. Deng, P. Wu, C. X. Cai, Adv. Healthcare Mater. 2016, 5, 2437. [149] Y. Z. Shen, Q. Tian, Y. D. Sun, J. J. Xu, D. J. Ye, H. Y. Chen, Anal. Chem. 2017, 89, 13610. [150] L. Zhou, Z. H. Li, E. G. Ju, Z. Liu, J. S. Ren, X. G. Qu, Small 2013, 9, 4262. [151] L. Zhou, Z. W. Chen, K. Dong, M. L. Yin, J. S. Ren, X. G. Qu, Biomaterials 2014, 35, 8694. [152] K. R. Deng, Z. Y. Hou, X. J. Li, C. X. Li, Y. X. Zhang, X. R. Deng, Z. Y. Cheng, J. Lin, Sci. Rep. 2015, 5, 7851. [153] Y. Wu, D. Li, F. Zhou, H. Liang, Y. Liu, W. Hou, Q. Yuan, X. Zhang, W. Tan, Chem. Sci. 2018, 9, 5427. [154] L. Ma, F. Liu, Z. Lei, Z. Wang, Biosens. Bioelectron. 2017, 87, 638. [155] J. Zhao, J. H. Gao, W. T. Xue, Z. H. Di, H. Xing, Y. Lu, L. L. Li, J. Am. Chem. Soc. 2018, 140, 578. [156] S. Han, A. Samanta, X. Xie, L. Huang, J. Peng, S. J. Park, D. B. L. Teh, Y. Choi, Y. T. Chang, A. H. All, Y. Yang, B. Xing, X. Liu, Adv. Mater. 2017, 29, 1700244. [157] L. L. Li, P. W. Wu, K. Hwang, Y. Lu, J. Am. Chem. Soc. 2013, 135, 2411. [158] L. L. Li, Y. Lu, J. Am. Chem. Soc. 2015, 137, 5272. [159] Q. Yuan, Y. Wu, J. Wang, D. Q. Lu, Z. L. Zhao, T. Liu, X. B. Zhang, W. H. Tan, Angew. Chem., Int. Ed. 2013, 52, 13965. [160] S. Fang, C. Wang, J. Xiang, L. Cheng, X. J. Song, L. G. Xu, R. Peng, Z. Liu, Nano Res. 2014, 7, 1327. [161] N. Wu, L. Bao, L. Ding, H. X. Ju, Angew. Chem., Int. Ed. 2016, 55, 5220.\nAdv. Healthcare Mater. 2019, 1801158\n1801158 (23 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\n[162] J. E. Rosen, L. Chan, D. B. Shieh, F. X. Gu, Nanomedicine 2012, 8, 275. [163] L. Zhang, W. F. Dong, H. B. Sun, Nanoscale 2013, 5, 7664. [164] J. K. Herr, J. E. Smith, C. D. Medley, D. Shangguan, W. Tan, Anal.\nChem. 2006, 78, 2918. [165] J. E. Smith, C. D. Medley, Z. W. Tang, D. Shangguan, C. Lofton,\nW. H. Tan, Anal. Chem. 2007, 79, 3075. [166] J. J. Li, S. Wang, C. Wu, Y. Dai, P. F. Hou, C. P. Han, K. Xu, Biosens.\nBioelectron. 2016, 86, 1047. [167] G. G. Westmeyer, Y. Durocher, A. Jasanoff, Angew. Chem., Int. Ed.\n2010, 49, 3909. [168] P. H. Zhang, J. T. Cao, Q. H. Min, J. J. Zhu, ACS Appl. Mater.\nInterfaces 2013, 5, 7417. [169] B. Yang, B. B. Chen, M. He, X. Yin, C. Xu, B. Hu, Anal. Chem.\n2018, 90, 2355. [170] H. Y. Ko, K. J. Choi, C. H. Lee, S. Kim, Biomaterials 2011, 32, 1130. [171] C. X. Wang, J. J. Zhou, P. Wang, W. S. He, H. W. Duan, Bioconjugate\nChem. 2016, 27, 815. [172] H. T. Zhu, L. R. Zhang, Y. F. Liu, Y. P. Zhou, K. Wang, X. D. Xie,\nL. Song, D. Q. Wang, C. L. Han, Q. Y. Chen, Sci. Rep. 2016, 6, 39245. [173] R. Yang, W. Y. Mu, Q. Y. Chen, Q. Wang, J. Gao, ACS Biomater. Sci. Eng. 2018, 4, 2606. [174] C. M. Li, T. Chen, I. Ocsoy, G. Z. Zhu, E. Yasun, M. X. You, C. C. Wu, J. Zheng, E. Q. Song, C. Z. Huang, W. H. Tan, Adv. Funct. Mater. 2014, 24, 1772. [175] A. Z. Wang, V. Bagalkot, C. C. Vasilliou, F. Gu, F. Alexis, L. Zhang, M. Shaikh, K. Yuet, M. J. Cima, R. Langer, P. W. Kantoff, N. H. Bander, S. Y. Jon, O. C. Farokhzad, ChemMedChem 2008, 3, 1311. [176] T. Chen, M. I. Shukoor, R. W. Wang, Z. L. Zhao, Q. Yuan, S. Bamrungsap, X. L. Xiong, W. H. Tan, ACS Nano 2011, 5, 7866. [177] M. K. Yu, D. Kim, I. H. Lee, J. S. So, Y. Y. Jeong, S. Jon, Small 2011, 7, 2241. [178] P. Wu, Y. Gao, H. Zhang, C. X. Cai, Anal. Chem. 2012, 84, 7692. [179] Z. Fan, D. Senapati, A. K. Singh, P. C. Ray, Mol. Pharmaceutics 2013, 10, 857. [180] Z. Fan, M. Shelton, A. K. Singh, D. Senapati, S. A. Khan, P. C. Ray, ACS Nano 2012, 6, 1065. [181] K. Roy, R. K. Kanwar, J. R. Kanwar, Biomaterials 2015, 71, 84. [182] Z. H. Cao, R. Tong, A. Mishra, W. C. Xu, G. C. L. Wong, J. J. Cheng, Y. Lu, Angew. Chem., Int. Ed. 2009, 48, 6494. [183] H. Xing, L. Tang, X. J. Yang, K. Hwang, W. D. Wang, Q. Yin,\nN. Y. Wong, L. W. Dobrucki, N. Yasui, J. A. Katzenellenbogen, W. G. Helferich, J. J. Cheng, Y. Lu, J. Mater. Chem. B 2013, 1, 5288. [184] K. C. Zhang, M. Liu, X. Y. Tong, N. Sun, L. Zhou, Y. Cao, J. E. Wang, H. L. Zhang, R. J. Pei, Biomacromolecules 2015, 16, 2618. [185] H. Xing, C. L. Zhang, G. Ruan, J. J. Zhang, K. Hwang, Y. Liu, Anal. Chem. 2016, 88, 1506. [186] M. W. Kim, H. Y. Jeong, S. J. Kang, M. J. Choi, Y. M. You, C. S. Im, T. S. Lee, I. H. Song, C. G. Lee, K. J. Rhee, Y. K. Lee, Y. S. Park, Sci. Rep. 2017, 7, 9474. [187] L. L. Li, Q. Yin, J. J. Cheng, Y. Lu, Adv. Healthcare Mater. 2012, 1, 567. [188] L. Tang, X. J. Yang, L. W. Dobrucki, I. Chaudhury, Q. Yin, C. Yao, S. Lezmi, W. G. Helferich, T. M. Fan, J. J. Cheng, Angew. Chem., Int. Ed. 2012, 51, 12721. [189] H. N. Li, Y. W. Mu, J. S. Lu, W. Wei, Y. K. Wan, S. Q. Liu, Anal. Chem. 2014, 86, 3602. [190] X. Y. Wang, P. S. Song, L. Peng, A. J. Tong, Y. Xiang, ACS Appl. Mater. Interfaces 2016, 8, 609. [191] L. Cai, Z. Z. Chen, M. Y. Chen, H. W. Tang, D. W. Pang, Biomaterials 2013, 34, 371. [192] Y. A. Zhang, S. Guo, S. B. Cheng, X. H. Ji, Z. K. He, Biosens. Bioelectron. 2017, 94, 478.\n[193] L. L. Li, M. Y. Xie, J. Wang, X. Y. Li, C. Wang, Q. Yuan, D. W. Pang, Y. Lu, W. H. Tan, Chem. Commun. 2013, 49, 5823. [194] J. T. Tan, N. Yang, L. P. Zhong, J. Tan, Z. X. Hu, Q. Zhao, W. L. Gong, Z. H. Zhang, R. Zheng, Z. Q. Lai, Y. M. Li, C. F. Zhou, G. Q. Zhang, D. Zheng, Y. Zhang, S. Y. Wu, X. L. Jiang, J. H. Zhong, Y. Huang, S. F. Zhou, Y. X. Zhao, Theranostics 2017, 7, 4862. [195] O. C. Farokhzad, A. Khademhosseini, S. Y. Yon, A. Hermann, J. J. Cheng, C. Chin, A. Kiselyuk, B. Teply, G. Eng, R. Langer, Anal. Chem. 2005, 77, 5453. [196] H. L. Gao, J. Qian, S. J. Cao, Z. Yang, Z. Q. Pang, S. Q. Pan, L. Fan, Z. J. Xi, X. G. Jiang, Q. Z. Zhang, Biomaterials 2012, 33, 5115. [197] H. L. Gao, J. Qian, Z. Yang, Z. Q. Pang, Z. J. Xi, S. J. Cao, Y. C. Wang, S. Q. Pan, S. Zhang, W. Wang, X. G. Jiang, Q. Z. Zhang, Biomaterials 2012, 33, 6264. [198] Y. K. Jung, M. A. Woo, H. T. Soh, H. G. Park, Chem. Commun. 2014, 50, 12329. [199] H. S. Wang, J. Li, J. Y. Li, K. Wang, Y. Ding, X. H. Xia, NPG Asia Mater. 2017, 9, e354. [200] P. Mohammadzadeh, R. A. Cohan, S. M. Ghoreishi, A. Bitarafan-Rajabi, M. S. Ardestani, Sci. Rep. 2017, 7, 11832. [201] H. H. Yan, X. H. Gao, Y. F. Zhang, W. J. Chang, J. H. Li, X. W. Li, Q. Du, C. Li, ACS Appl. Mater. Interfaces 2018, 10, 17047. [202] J. W. Tian, L. Ding, H. X. Ju, Y. C. Yang, X. L. Li, Z. Shen, Z. Zhu, J. S. Yu, C. J. Yang, Angew. Chem., Int. Ed. 2014, 53, 9544. [203] D. L. Wang, B. Liu, Y. Ma, C. W. Wu, Q. B. Mou, H. P. Deng, R. B. Wang, D. Y. Yan, C. Zhang, X. Y. Zhu, J. Am. Chem. Soc. 2017, 139, 14021. [204] J. J. Li, J. You, Y. Dai, M. L. Shi, C. P. Han, K. Xu, Anal. Chem. 2014, 86, 11306. [205] T. R. Kuo, W. Y. Lai, C. H. Li, Y. H. Wun, H. C. Chang, J. S. Chen, P. Yang, C. C. Chen, Nano Res. 2014, 7, 658. [206] C. S. Zhou, T. Chen, C. C. Wu, G. Z. Zhu, L. P. Qiu, C. Cui, W. J. Hou, W. H. Tan, Chem. – Asian J. 2015, 10, 166. [207] W. B. Qiang, H. T. Hu, L. Sun, H. Li, D. K. Xu, Anal. Chem. 2015, 87, 12190. [208] W. Tao, X. W. Zeng, J. Wu, X. Zhu, X. H. Yu, X. D. Zhang, J. X. Zhang, G. Liu, L. Mei, Theranostics 2016, 6, 470. [209] L. Jia, L. Ding, J. W. Tian, L. Bao, Y. P. Hu, H. X. Ju, J. S. Yu, Nanoscale 2015, 7, 15953. [210] C. H. Wang, Y. F. Huang, C. K. Yeh, Langmuir 2011, 27, 6971. [211] Z. Fan, L. M. Sun, Y. J. Huang, Y. Z. Wang, M. J. Zhang, Nat. Nanotechnol. 2016, 11, 388. [212] P. F. Zhang, Z. Zhao, C. S. Li, H. F. Su, Y. Y. Wu, R. T. K. Kwok,\nJ. W. Y. Lam, P. Gong, L. T. Cai, B. Z. Tang, Anal. Chem. 2018, 90, 1063. [213] Z. L. Zhao, H. H. Fan, G. F. Zhou, H. R. Bai, H. Liang, R. W. Wang, X. B. Zhang, W. H. Tan, J. Am. Chem. Soc. 2014, 136, 11220. [214] S. K. Silverman, RNA 2003, 9, 377. [215] M. Famulok, J. S. Hartig, G. Mayer, Chem. Rev. 2007, 107, 3715. [216] G. A. Soukup, R. R. Breaker, Trends Biotechnol. 1999, 17, 469. [217] Z. J. Zhou, L. Xiao, Y. Xiang, J. Zhou, A. J. Tong, Anal. Chim. Acta\n2015, 889, 179. [218] J. W. Liu, Y. Lu, Anal. Chem. 2004, 76, 1627. [219] S. Ayukawa, Y. Sakai, D. Kiga, Chem. Commun. 2012, 48, 7556. [220] Y. Yang, J. Huang, X. Yang, K. Quan, H. Wang, L. Ying, N. Xie, M. Ou, K. Wang, Anal. Chem. 2016, 88, 5981. [221] P. Yang, J. Wang, Q. Pang, F. Zhang, J. Wang, Q. Wang, Q. Qi, Metab. Eng. 2017, 43, 21. [222] M. Wieland, B. Berschneider, M. D. Erlacher, J. S. Hartig, Chem. Biol. 2010, 17, 236. [223] A. Ogawa, M. Maeda, ChemBioChem 2008, 9, 206. [224] M. Wieland, J. S. Hartig, Angew. Chem., Int. Ed. 2008, 47, 2604. [225] B. Berschneider, M. Wieland, M. Rubini, J. S. Hartig, Angew.\nChem., Int. Ed. 2009, 48, 7564.\nAdv. Healthcare Mater. 2019, 1801158\n1801158 (24 of 24)\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\n[226] D. Kumar, C. I. An, Y. Yokobayashi, J. Am. Chem. Soc. 2009, 131, 13906. [227] M. N. Win, C. D. Smolke, Science 2008, 322, 456. [228] P. Ketzer, S. F. Haas, S. Engelhardt, J. S. Hartig, D. M. Nettelbeck, Nucleic Acids Res. 2012, 40, e167. [229] P. Ketzer, J. K. Kaufmann, S. Engelhardt, S. Bossow, C. von Kalle,\nJ. S. Hartig, G. Ungerechts, D. M. Nettelbeck, Proc. Natl. Acad. Sci. USA 2014, 111, E554.\n[230] G. Zhong, H. Wang, C. C. Bailey, G. Gao, M. Farzan, eLife 2016, 5, e18858. [231] W. Tang, J. H. Hu, D. R. Liu, Nat. Commun. 2017, 8, 15939. [232] X. Wu, J. Chen, M. Wu, J. X. J. Zhao, Theranostics 2015, 5, 322. [233] Z. M. Ying, Z. Wu, B. Tu, W. H. Tan, J. H. Jiang, J. Am. Chem. Soc. 2017, 139, 9779. [234] D. Q. Lu, L. He, G. Zhang, A. P. Lv, R. W. Wang, X. B. Zhang,\nW. H. Tan, Nanophotonics 2017, 6, 109.\nAdv. Healthcare Mater. 2019, 1801158"
    } ],
    "references" : [ {
      "title" : "Chem",
      "author" : [ "Z.D. Wang", "Y. Lu", "J. Mater" ],
      "venue" : "2009, 19,",
      "citeRegEx" : "11",
      "shortCiteRegEx" : null,
      "year" : 1788
    }, {
      "title" : "Chem",
      "author" : [ "S.Q. Hu", "B.Y. Ye", "H.L. Tang", "F. Wu", "X.Y. Yi", "T.T. Yi", "D.H. Wu", "L. Wu", "J.X. Wang", "J. Mater" ],
      "venue" : "B 2018, 6,",
      "citeRegEx" : "90",
      "shortCiteRegEx" : null,
      "year" : 1187
    }, {
      "title" : "Chem",
      "author" : [ "A. Pramanik", "S.R. Chavva", "Z. Fan", "S.S. Sinha", "B. Priya", "V. Nellore", "P.C. Ray", "J. Phys" ],
      "venue" : "Lett. 2014, 5,",
      "citeRegEx" : "102",
      "shortCiteRegEx" : null,
      "year" : 2150
    }, {
      "title" : "Biol",
      "author" : [ "K.K. Alam", "K.D. Tawiah", "M.F. Lichte", "D. Porciani", "D.H. Burke", "ACS Synth" ],
      "venue" : "2017, 6,",
      "citeRegEx" : "131",
      "shortCiteRegEx" : null,
      "year" : 1710
    }, {
      "title" : "Chem",
      "author" : [ "L.L. Li", "P.W. Wu", "K. Hwang", "Y. Lu", "J. Am" ],
      "venue" : "Soc. 2013, 135,",
      "citeRegEx" : "157",
      "shortCiteRegEx" : null,
      "year" : 2411
    }, {
      "title" : "Sci",
      "author" : [ "R. Yang", "W.Y. Mu", "Q.Y. Chen", "Q. Wang", "J. Gao", "ACS Biomater" ],
      "venue" : "Eng. 2018, 4,",
      "citeRegEx" : "173",
      "shortCiteRegEx" : null,
      "year" : 2606
    } ],
    "referenceMentions" : [ {
      "referenceID" : 1,
      "context" : "More recently, Hu et al.[90] reported another fluorescent monometallic Ag nanohybrids (Ag NHs) synthesized via polycytosine-mediated Ag NC biomineralization on Ag NPs.",
      "startOffset" : 24,
      "endOffset" : 28
    }, {
      "referenceID" : 2,
      "context" : "With the extremely high two-photon absorption cross-section from GO, Pramanik et al.[102] reported a selective two-photon imaging of SK-BR-3 breast tumor cell in second biological transparency windows using 1100 nm wavelength.",
      "startOffset" : 84,
      "endOffset" : 89
    }, {
      "referenceID" : 3,
      "context" : "Other in vivo applications including the monitoring of RNA−RNA hybridization,[131] in vivo aptamer photoregulation,[132] specific imaging of cell-surface glycosylation,[133] and mRNA detection[134] have also been developed based on the integration of aptamers with DNA nanostructures, such as Split-Broccoli assembles,[131] a photolabile oligonucleotide complex,[132] hybridization chain reaction (HCR) nanoassemblies,[133] and DNA nanotube.",
      "startOffset" : 77,
      "endOffset" : 82
    }, {
      "referenceID" : 3,
      "context" : "Other in vivo applications including the monitoring of RNA−RNA hybridization,[131] in vivo aptamer photoregulation,[132] specific imaging of cell-surface glycosylation,[133] and mRNA detection[134] have also been developed based on the integration of aptamers with DNA nanostructures, such as Split-Broccoli assembles,[131] a photolabile oligonucleotide complex,[132] hybridization chain reaction (HCR) nanoassemblies,[133] and DNA nanotube.",
      "startOffset" : 318,
      "endOffset" : 323
    }, {
      "referenceID" : 4,
      "context" : "To address this issue, Li et al.[157] developed a facile one-step ligand exchange strategy to prepare uniform aptamer-modified UCNPs as versatile bioprobes.",
      "startOffset" : 32,
      "endOffset" : 37
    }, {
      "referenceID" : 5,
      "context" : "Reproduced with permission.[173] Copyright 2018, American Chemical Society.",
      "startOffset" : 27,
      "endOffset" : 32
    }, {
      "referenceID" : 5,
      "context" : "In the past decade, various aptamer-functionalized magnetic nanomaterials have been developed,[162,163] and applied for diverse in vivo applications, including isolation and detection of cancer cells,[164–166] sensing and imaging,[167–172] delivery of therapeutic agents,[173] and cancer imaging and therapy.",
      "startOffset" : 271,
      "endOffset" : 276
    }, {
      "referenceID" : 5,
      "context" : "Yang et al.[173] (Figure 9D) constructed a smart magnetic nanoaptamer based on the assembly of DNA-templated Fe3O4, hydrophobic dye, HIF-1α and glucose transporter 1 aptamers, and siRNA.",
      "startOffset" : 11,
      "endOffset" : 16
    } ],
    "year" : 2019,
    "abstractText" : "DOI: 10.1002/adhm.201801158 equally exciting and perhaps more challenging field of application is toward their in vivo applications, including living animals and human bodies, in diverse areas,[2] such as sensing, drug delivery, medical imaging, and cancer therapy. However, most of these nanomaterials lack selectivity toward targets of interests. Therefore, to employ these nanomaterials for a wider range of in vivo applications, various molecular engineering approaches have been employed to obtained nanomaterials functionalized with biomolecules to enable selective targeting.[3–5] Among these biomolecules, functional nucleic acids, or FNAs, have shown the most promise. FNAs are DNA or RNA molecules that can interact with or bind to a specific analyte, resulting in a conformational change and/or a catalytic reaction.[6] As their names suggested, ribozymes and deoxyribozymes (called DNAzyme hereafter) can act as enzymes in the presence of cofactors to catalyze various reactions, including cleavage and ligation of RNA/DNA, and phosphorylation and peroxidation of DNA. On the other hand, riboswitches and DNA aptamers are antibody-like receptors that can bind target molecules with high affinity and selectivity. Furthermore, the binding abilities of riboswitches and aptamers can be combined with the enzymatic function of ribozymes or DNAzymes to form aptazymes so that the binding of targets can inhibit or enhance the catalytic activities. These nucleic acids, including DNAzymes, aptamers, and aptazymes, are collectively known as FNAs to emphasize their functions beyond the traditional genetic storage and transformations roles for DNA and RNA. Unlike DNA and RNA inside biological systems, FNAs are isolated via a combinatorial technique known as in vitro selection, or a process also known as systematic evolution of ligands by exponential enrichment (SELEX). The discovery of new functions of nucleic acids has not only resulted in major advances in the fields of molecular biology and biochemistry, but also revolutionized sensors designs for both in vitro and in vivo applications.[7,8] Over the past decade, numerous FNA-based nanomaterials have been developed.[9–12] Among these FNA-based nanosystems, the functions of FNAs can be categorized into two types: diagnostic function and therapeutic function. For the diagnostic function, the FNAs serve either as the biorecognition ligands for direct sensing and imaging of the Recent advances in nanotechnology and engineering have generated many nanomaterials with unique physical and chemical properties. Over the past decade, numerous nanomaterials are introduced into many research areas, such as sensors for environmental monitoring, food safety, point-ofcare diagnostics, and as transducers for solar energy transfer. Meanwhile, functional nucleic acids (FNAs), including nucleic acid enzymes, aptamers, and aptazymes, have attracted major attention from the biomedical community due to their unique target recognition and catalytic properties. Benefiting from the recent progress of molecular engineering strategies, the physicochemical properties of nanomaterials are endowed by the target recognition and catalytic activity of FNAs in the presence of a target analyte, resulting in numerous smart nanoprobes for diverse applications including intracellular imaging, drug delivery, in vivo imaging, and tumor therapy. This progress report focuses on the recent advances in designing and engineering FNA-based nanomaterials, highlighting the functional outcomes toward in vivo applications. The challenges and opportunities for the future translation of FNA-based nanomaterials into clinical applications are also discussed. Functional Nucleic Acid",
    "creator" : "Adobe InDesign CS6 (Macintosh)"
  }
}